<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Bull World Health Organ</journal-id><journal-id journal-id-type="iso-abbrev">Bull. World Health Organ</journal-id><journal-id journal-id-type="publisher-id">BLT</journal-id><journal-title-group><journal-title>Bulletin of the World Health Organization</journal-title></journal-title-group><issn pub-type="ppub">0042-9686</issn><issn pub-type="epub">1564-0604</issn><publisher><publisher-name>World Health Organization</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26478626</article-id><article-id pub-id-type="pmc">4581638</article-id><article-id pub-id-type="publisher-id">BLT.14.146480</article-id><article-id pub-id-type="doi">10.2471/BLT.14.146480</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Errors generated by a point-of-care CD4+ T-lymphocyte analyser: a retrospective observational study in nine countries</article-title><trans-title-group xml:lang="fr"><trans-title xml:lang="fr">Erreurs g&#x000e9;n&#x000e9;r&#x000e9;es par l'analyseur de lymphocytes&#x000a0;T CD4+ sur le lieu d'intervention: une &#x000e9;tude r&#x000e9;trospective par observation dans neuf pays</trans-title></trans-title-group><trans-title-group xml:lang="es"><trans-title xml:lang="es">Errores generados por un analizador de linfocitos en el punto de atenci&#x000f3;n CD4+ T: un estudio observacional retrospectivo en nueve pa&#x000ed;ses</trans-title></trans-title-group><trans-title-group xml:lang="ar"><trans-title xml:lang="ar">&#x00627;&#x00644;&#x00623;&#x0062e;&#x00637;&#x00627;&#x00621; &#x00627;&#x00644;&#x00635;&#x00627;&#x0062f;&#x00631;&#x00629; &#x00628;&#x00641;&#x00639;&#x00644; &#x0062c;&#x00647;&#x00627;&#x00632; &#x0062a;&#x0062d;&#x00644;&#x0064a;&#x00644; &#x0062e;&#x00644;&#x00627;&#x0064a;&#x00627; &#x00627;&#x00644;&#x00644;&#x00645;&#x00641;&#x00627;&#x00648;&#x0064a;&#x00627;&#x0062a; &#x00627;&#x00644;&#x0062a;&#x00627;&#x00626;&#x0064a;&#x00629; CD4+ &#x00644;&#x00646;&#x00642;&#x00637;&#x00629; &#x00627;&#x00644;&#x00631;&#x00639;&#x00627;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00633;&#x00631;&#x0064a;&#x00631;&#x0064a;&#x00629;: &#x0062f;&#x00631;&#x00627;&#x00633;&#x00629;&#x000a0;&#x00631;&#x00635;&#x0062f;&#x0064a;&#x00629;&#x000a0;&#x00628;&#x00623;&#x0062b;&#x00631;&#x000a0;&#x00631;&#x0062c;&#x00639;&#x0064a;&#x000a0;&#x00641;&#x0064a;&#x000a0;&#x0062a;&#x00633;&#x00639;&#x00629;&#x000a0;&#x00628;&#x00644;&#x0062f;&#x00627;&#x00646; </trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title xml:lang="zh">&#x0533b;&#x07597;&#x070b9;&#x07684;&#x000a0;CD4+&#x000a0;T-&#x06dcb;&#x05df4;&#x07ec6;&#x080de;&#x05206;&#x06790;&#x05668;&#x04ea7;&#x0751f;&#x07684;&#x09519;&#x08bef;&#x0ff1a; &#x04e00;&#x09879;&#x05728;&#x04e5d;&#x04e2a;&#x056fd;&#x05bb6;&#x05f00;&#x05c55;&#x07684;&#x056de;&#x0987e;&#x06027;&#x089c2;&#x05bdf;&#x07814;&#x07a76;</trans-title></trans-title-group><trans-title-group xml:lang="ru"><trans-title xml:lang="ru">&#x0041e;&#x00448;&#x00438;&#x00431;&#x0043a;&#x00438; &#x00430;&#x0043d;&#x00430;&#x0043b;&#x00438;&#x00437;&#x00430;&#x00442;&#x0043e;&#x00440;&#x00430; &#x0043f;&#x00440;&#x00438; &#x0043f;&#x0043e;&#x00434;&#x00441;&#x00447;&#x00435;&#x00442;&#x00435; CD4+ T-&#x0043b;&#x00438;&#x0043c;&#x00444;&#x0043e;&#x00446;&#x00438;&#x00442;&#x0043e;&#x00432; &#x00432; &#x0043f;&#x00443;&#x0043d;&#x0043a;&#x00442;&#x00435; &#x0043f;&#x00435;&#x00440;&#x00432;&#x00438;&#x00447;&#x0043d;&#x0043e;&#x00433;&#x0043e; &#x0043e;&#x00431;&#x00440;&#x00430;&#x00449;&#x00435;&#x0043d;&#x00438;&#x0044f;: &#x00440;&#x00435;&#x00442;&#x00440;&#x0043e;&#x00441;&#x0043f;&#x00435;&#x0043a;&#x00442;&#x00438;&#x00432;&#x0043d;&#x0043e;&#x00435; &#x0043e;&#x00431;&#x00441;&#x00435;&#x00440;&#x00432;&#x00430;&#x00446;&#x00438;&#x0043e;&#x0043d;&#x0043d;&#x0043e;&#x00435; &#x00438;&#x00441;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x00435; &#x00432; &#x00434;&#x00435;&#x00432;&#x0044f;&#x00442;&#x00438; &#x00441;&#x00442;&#x00440;&#x00430;&#x0043d;&#x00430;&#x00445;</trans-title></trans-title-group><alt-title alt-title-type="author-running-head">Emmanuel Fajardo et al.</alt-title><alt-title alt-title-type="title-running-head">CD4+ analysis</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Fajardo</surname><given-names>Emmanuel</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Metcalf</surname><given-names>Carol</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Piriou</surname><given-names>Erwan</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gueguen</surname><given-names>Monique</given-names></name><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Maman</surname><given-names>David</given-names></name><xref ref-type="aff" rid="aff4"><sup>d</sup></xref></contrib><contrib contrib-type="author"><name><surname>Chaillet</surname><given-names>Pascale</given-names></name><xref ref-type="aff" rid="aff5"><sup>e</sup></xref></contrib><contrib contrib-type="author"><name><surname>Cox</surname><given-names>Vivian</given-names></name><xref ref-type="aff" rid="aff6"><sup>f</sup></xref></contrib><contrib contrib-type="author"><name><surname>Rumaney</surname><given-names>Maryam B</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tunggal</surname><given-names>Syanness</given-names></name><xref ref-type="aff" rid="aff7"><sup>g</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kosack</surname><given-names>Cara</given-names></name><xref ref-type="aff" rid="aff8"><sup>h</sup></xref></contrib><contrib contrib-type="author"><name><surname>Roberts</surname><given-names>Teri</given-names></name><xref ref-type="aff" rid="aff9"><sup>i</sup></xref></contrib><aff id="aff1"><label>a</label>M&#x000e9;decins Sans Fronti&#x000e8;res (MSF), Southern Africa Medical Unit (SAMU), Waverly Business Park, 303 A&#x00026;B, Cape Town, <country>South Africa</country>.</aff><aff id="aff2"><label>b</label>MSF, Operational Centre Amsterdam, <country>Netherlands</country>.</aff><aff id="aff3"><label>c</label>MSF, Operational Centre Paris, <country>France</country>.</aff><aff id="aff4"><label>d</label>MSF, Epicentre Paris, <country>France</country>.</aff><aff id="aff5"><label>e</label>MSF, Operational Centre Brussels, <country>Belgium</country>.</aff><aff id="aff6"><label>f</label>MSF, Khayelitsha, <country>South Africa</country>.</aff><aff id="aff7"><label>g</label>MSF, Roma, <country>Lesotho</country>.</aff><aff id="aff8"><label>h</label>MSF, Diagnostic Network, Amsterdam, <country>Netherlands</country>.</aff><aff id="aff9"><label>i</label>MSF, Access Campaign, Geneva, <country>Switzerland</country>.</aff></contrib-group><author-notes><corresp id="cor1">Correspondence to Emmanuel Fajardo (email: <email xlink:href="emmanuel.fajardo@joburg.msf.org">emmanuel.fajardo@joburg.msf.org</email>).</corresp></author-notes><pub-date pub-type="ppub"><day>01</day><month>9</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>25</day><month>6</month><year>2015</year></pub-date><volume>93</volume><issue>9</issue><fpage>623</fpage><lpage>630</lpage><history><date date-type="received"><day>31</day><month>8</month><year>2014</year></date><date date-type="rev-recd"><day>14</day><month>5</month><year>2015</year></date><date date-type="accepted"><day>21</day><month>5</month><year>2015</year></date></history><permissions><copyright-statement>(c) 2015 The authors; licensee World Health Organization.</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution IGO License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/igo/legalcode">http://creativecommons.org/licenses/by/3.0/igo/legalcode</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In any reproduction of this article there should not be any suggestion that WHO or this article endorse any specific organization or products. The use of the WHO logo is not permitted. This notice should be preserved along with the article's original URL.</license-p></license></permissions><abstract><title>Abstract</title><sec><title>Objective</title><p>To estimate the proportion of invalid results generated by a CD4+ T-lymphocyte analyser used by M&#x000e9;decins Sans Fronti&#x000e8;res (MSF) in field projects and identify factors associated with invalid results.</p></sec><sec><title>Methods</title><p>We collated 25&#x02009;616 CD4+ T-lymphocyte test results from 39 sites in nine countries for the years 2011 to 2013. Information about the setting, user, training, sampling technique and device repair history were obtained by questionnaire. The analyser performs a series of checks to ensure that all steps of the analysis are completed successfully; if not, an invalid result is reported. We calculated the proportion of invalid results by device and by operator. Regression analyses were used to investigate factors associated with invalid results.</p></sec><sec><title>Findings</title><p>There were 3354 invalid test results (13.1%) across 39 sites, for 58 Alere Pima<sup>TM</sup> devices and 180 operators. The median proportion of errors per device and operator was 12.7% (interquartile range, IQR: 10.3&#x02013;19.9) and 12.1% (IQR: 7.1&#x02013;19.2), respectively. The proportion of invalid results varied widely by country, setting, user and device. Errors were not associated with settings, user experience or the number of users per device. Tests performed on capillary blood samples were significantly less likely to generate errors compared to venous whole blood.</p></sec><sec><title>Conclusion</title><p>The Alere Pima CD4+ analyser generated a high proportion of invalid test results, across different countries, settings and users. Most error codes could be attributed to the operator, but the exact causes proved difficult to identify. Invalid results need to be factored into the implementation and operational costs of routine CD4+ T-lymphocyte testing.</p></sec></abstract><trans-abstract xml:lang="fr"><title>R&#x000e9;sum&#x000e9;</title><sec><title>Objectif</title><p>Estimer la proportion de r&#x000e9;sultats non valides g&#x000e9;n&#x000e9;r&#x000e9;s par l'analyseur de lymphocytes&#x000a0;T CD4+ utilis&#x000e9; par M&#x000e9;decins Sans Fronti&#x000e8;res (MSF) dans les projets de terrain et d&#x000e9;terminer les facteurs associ&#x000e9;s aux r&#x000e9;sultats non valides.</p></sec><sec><title>M&#x000e9;thodes</title><p>Nous avons rassembl&#x000e9; 25&#x000a0;616 r&#x000e9;sultats de tests des lymphocytes&#x000a0;T CD4+ r&#x000e9;alis&#x000e9;s sur 39&#x000a0;sites dans neuf pays entre 2011 et 2013. Un questionnaire a permis d'obtenir des informations sur le lieu, l'utilisateur, la formation, la m&#x000e9;thode d'&#x000e9;chantillonnage et les r&#x000e9;parations effectu&#x000e9;es sur l'appareil. L'analyseur r&#x000e9;alise une s&#x000e9;rie de contr&#x000f4;les afin de garantir que toutes les &#x000e9;tapes de l'analyse se d&#x000e9;roulent correctement; si ce n'est pas le cas, il indique un r&#x000e9;sultat non valide. Nous avons calcul&#x000e9; la proportion de r&#x000e9;sultats non valides par appareil et par op&#x000e9;rateur. Des analyses de r&#x000e9;gression ont permis de rechercher les facteurs associ&#x000e9;s aux r&#x000e9;sultats non valides.</p></sec><sec><title>R&#x000e9;sultats</title><p>Nous avons relev&#x000e9; 3354&#x000a0;r&#x000e9;sultats de tests non valides (13,1%) sur les 39&#x000a0;sites, avec 58&#x000a0;appareils Alere PimaTM et 180&#x000a0;op&#x000e9;rateurs. La proportion moyenne d'erreurs par appareil et par op&#x000e9;rateur &#x000e9;tait respectivement de 12,7% (intervalle interquartile, IQR: 10,3&#x02013;19,9) et de 12,1% (IQR: 7,1-19,2). La proportion de r&#x000e9;sultats non valides variait consid&#x000e9;rablement en fonction du pays, du lieu, de l'utilisateur et de l'appareil. Les erreurs n'&#x000e9;taient pas associ&#x000e9;es aux lieux, &#x000e0; l'exp&#x000e9;rience de l'utilisateur ou au nombre d'utilisateurs par appareil. Les tests effectu&#x000e9;s sur des pr&#x000e9;l&#x000e8;vements de sang capillaire &#x000e9;taient nettement moins susceptibles de g&#x000e9;n&#x000e9;rer des erreurs que ceux r&#x000e9;alis&#x000e9;s sur du sang veineux total.</p></sec><sec><title>Conclusion</title><p>L'analyseur de CD4+ Alere Pima a g&#x000e9;n&#x000e9;r&#x000e9; une proportion &#x000e9;lev&#x000e9;e de r&#x000e9;sultats de tests non valides, dans diff&#x000e9;rents pays, diff&#x000e9;rents lieux et avec diff&#x000e9;rents utilisateurs. La plupart des codes d'erreur ont pu &#x000ea;tre imput&#x000e9;s &#x000e0; l'op&#x000e9;rateur, mais les causes exactes se sont av&#x000e9;r&#x000e9;es difficiles &#x000e0; d&#x000e9;terminer. Les r&#x000e9;sultats non valides doivent &#x000ea;tre pris en compte dans les co&#x000fb;ts de mise en &#x00153;uvre et d'exploitation des tests de routine des lymphocytes&#x000a0;T CD4+.</p></sec></trans-abstract><trans-abstract xml:lang="es"><title>Resumen</title><sec><title>Objetivo</title><p>Estimar la proporci&#x000f3;n de resultados no v&#x000e1;lidos generados por un analizador de linfocitos CD4+ T utilizado por M&#x000e9;dicos sin Fronteras (MSF) en proyectos de campo e identificar los factores asociados a los resultados no v&#x000e1;lidos.</p></sec><sec><title>M&#x000e9;todos</title><p>Se recopilaron 25 616 resultados de pruebas de linfocitos CD4+ T de 39 localizaciones en nueve pa&#x000ed;ses entre los a&#x000f1;os 2011 y 2013. La informaci&#x000f3;n sobre el entorno, los usuarios, la formaci&#x000f3;n, la t&#x000e9;cnica de muestreo y el historial de reparaci&#x000f3;n del dispositivo se obtuvo a trav&#x000e9;s de un cuestionario. El analizador lleva a cabo una serie de chequeos para asegurar que se completan con &#x000e9;xito todos los pasos del an&#x000e1;lisis; si no es as&#x000ed;, se informa de un resultado no v&#x000e1;lido. Se calcul&#x000f3; la proporci&#x000f3;n de resultados no v&#x000e1;lidos por dispositivo y operador. Se utilizaron an&#x000e1;lisis de regresi&#x000f3;n para investigar los factores asociados con los resultados no v&#x000e1;lidos.</p></sec><sec><title>Resultados</title><p>Hubo 3354 resultados no v&#x000e1;lidos de pruebas (13,1%) en 39 localizaciones, para 58 dispositivos Alere Pima<sup>TM</sup> y 180 operadores. La proporci&#x000f3;n media de errores por dispositivo y operador fue del 12,7% (rango intercuart&#x000ed;lico, RIC: 10,3&#x02013;19,9) y del 12,1% (RIC: 7,1-19,2), respectivamente. La proporci&#x000f3;n de resultados no v&#x000e1;lidos vari&#x000f3; ampliamente entre pa&#x000ed;ses, entornos, usuarios y dispositivos. Los errores no estaban asociados con los entornos, la experiencia del usuario o el n&#x000fa;mero de usuarios por dispositivo. Las pruebas realizadas con muestras de sangre capilar ten&#x000ed;an menos posibilidades de generar error que las realizadas con sangre entera venosa.</p></sec><sec><title>Conclusi&#x000f3;n</title><p>El analizador Alere Pima CD4+ gener&#x000f3; una alta proporci&#x000f3;n de resultados no v&#x000e1;lidos de pruebas en diferentes pa&#x000ed;ses, entornos y usuarios. La mayor&#x000ed;a de los c&#x000f3;digos de error podr&#x000ed;an atribuirse al operador, pero result&#x000f3; dif&#x000ed;cil identificar las causas exactas. Los resultados no v&#x000e1;lidos de las pruebas rutinarias de linfocitos CD4+ T deber&#x000ed;an tenerse en cuenta en la aplicaci&#x000f3;n y los costes operacionales.</p></sec></trans-abstract><trans-abstract xml:lang="ar"><title>&#x00645;&#x00644;&#x0062e;&#x00635; </title><sec><title>&#x00627;&#x00644;&#x0063a;&#x00631;&#x00636; </title><p>&#x0062a;&#x00642;&#x0062f;&#x0064a;&#x00631; &#x00646;&#x00633;&#x00628;&#x00629; &#x00627;&#x00644;&#x00646;&#x0062a;&#x00627;&#x00626;&#x0062c; &#x0063a;&#x0064a;&#x00631; &#x00627;&#x00644;&#x00635;&#x00627;&#x00644;&#x0062d;&#x00629; &#x00627;&#x00644;&#x00635;&#x00627;&#x0062f;&#x00631;&#x00629; &#x00639;&#x00646; &#x0062c;&#x00647;&#x00627;&#x00632; &#x0062a;&#x0062d;&#x00644;&#x0064a;&#x00644; &#x0062e;&#x00644;&#x00627;&#x0064a;&#x00627; &#x00627;&#x00644;&#x00644;&#x00645;&#x00641;&#x00627;&#x00648;&#x0064a;&#x00627;&#x0062a; &#x00627;&#x00644;&#x0062a;&#x00627;&#x00626;&#x0064a;&#x00629; &#x0200e;CD4+ &#x00627;&#x00644;&#x00630;&#x0064a; &#x0062a;&#x00633;&#x0062a;&#x0062e;&#x0062f;&#x00645;&#x00647; &#x00645;&#x00646;&#x00638;&#x00645;&#x00629; &#x00623;&#x00637;&#x00628;&#x00627;&#x00621; &#x00628;&#x00644;&#x00627; &#x0062d;&#x0062f;&#x00648;&#x0062f; (MSF) &#x00641;&#x0064a; &#x00627;&#x00644;&#x00645;&#x00634;&#x00631;&#x00648;&#x00639;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00645;&#x0064a;&#x0062f;&#x00627;&#x00646;&#x0064a;&#x00629; &#x00648;&#x0062a;&#x0062d;&#x0062f;&#x0064a;&#x0062f; &#x00627;&#x00644;&#x00639;&#x00648;&#x00627;&#x00645;&#x00644; &#x00627;&#x00644;&#x00645;&#x00631;&#x0062a;&#x00628;&#x00637;&#x00629; &#x00628;&#x00627;&#x00644;&#x00646;&#x0062a;&#x00627;&#x00626;&#x0062c; &#x0063a;&#x0064a;&#x00631; &#x00627;&#x00644;&#x00635;&#x00627;&#x00644;&#x0062d;&#x00629;. </p></sec><sec><title>&#x00627;&#x00644;&#x00637;&#x00631;&#x0064a;&#x00642;&#x00629; </title><p>&#x00644;&#x00642;&#x0062f; &#x0062c;&#x00645;&#x00639;&#x00646;&#x00627; 25,616 &#x00646;&#x0062a;&#x0064a;&#x0062c;&#x00629; &#x00627;&#x0062e;&#x0062a;&#x00628;&#x00627;&#x00631; &#x00644;&#x0062e;&#x00644;&#x00627;&#x0064a;&#x00627; &#x00627;&#x00644;&#x00644;&#x00645;&#x00641;&#x00627;&#x00648;&#x0064a;&#x00627;&#x0062a; &#x00627;&#x00644;&#x0062a;&#x00627;&#x00626;&#x0064a;&#x00629; CD4+ &#x00645;&#x00646; 39&#x000a0;&#x00645;&#x00648;&#x00642;&#x00639;&#x0064b;&#x00627; &#x00641;&#x0064a; &#x0062a;&#x00633;&#x00639;&#x00629; &#x00628;&#x00644;&#x0062f;&#x00627;&#x00646; &#x00641;&#x0064a; &#x00627;&#x00644;&#x00641;&#x0062a;&#x00631;&#x00629; &#x00645;&#x00627; &#x00628;&#x0064a;&#x00646; &#x00639;&#x00627;&#x00645;&#x0064a;&#x00651; 2011 &#x00625;&#x00644;&#x00649;&#x000a0;2013. &#x00648;&#x0062a;&#x00645; &#x00627;&#x00644;&#x0062d;&#x00635;&#x00648;&#x00644; &#x00639;&#x00644;&#x00649; &#x00645;&#x00639;&#x00644;&#x00648;&#x00645;&#x00627;&#x0062a; &#x00639;&#x00646; &#x00627;&#x00644;&#x00628;&#x0064a;&#x00626;&#x00629;&#x0060c; &#x00648;&#x00627;&#x00644;&#x00645;&#x00633;&#x0062a;&#x0062e;&#x0062f;&#x00645;&#x0064a;&#x00646;&#x0060c; &#x00648;&#x00627;&#x00644;&#x0062a;&#x0062f;&#x00631;&#x0064a;&#x00628;&#x0060c; &#x00648;&#x0062a;&#x00642;&#x00646;&#x0064a;&#x00629; &#x00633;&#x0062d;&#x00628; &#x00627;&#x00644;&#x00639;&#x0064a;&#x00646;&#x00627;&#x0062a;&#x0060c; &#x00648;&#x0062a;&#x00627;&#x00631;&#x0064a;&#x0062e; &#x00625;&#x00635;&#x00644;&#x00627;&#x0062d; &#x00627;&#x00644;&#x0062c;&#x00647;&#x00627;&#x00632; &#x00639;&#x00646; &#x00637;&#x00631;&#x0064a;&#x00642; &#x00627;&#x00644;&#x00627;&#x00633;&#x0062a;&#x00628;&#x0064a;&#x00627;&#x00646;. &#x0064a;&#x00642;&#x00648;&#x00645; &#x0062c;&#x00647;&#x00627;&#x00632; &#x00627;&#x00644;&#x0062a;&#x0062d;&#x00644;&#x0064a;&#x00644; &#x00628;&#x00625;&#x0062c;&#x00631;&#x00627;&#x00621; &#x00633;&#x00644;&#x00633;&#x00644;&#x00629; &#x00645;&#x00646; &#x00639;&#x00645;&#x00644;&#x0064a;&#x00627;&#x0062a; &#x00627;&#x00644;&#x0062a;&#x0062d;&#x00642;&#x00642; &#x00644;&#x00644;&#x0062a;&#x00623;&#x00643;&#x0062f; &#x00645;&#x00646; &#x00627;&#x00643;&#x0062a;&#x00645;&#x00627;&#x00644; &#x0062c;&#x00645;&#x0064a;&#x00639; &#x0062e;&#x00637;&#x00648;&#x00627;&#x0062a; &#x00627;&#x00644;&#x0062a;&#x0062d;&#x00644;&#x0064a;&#x00644; &#x00628;&#x00646;&#x0062c;&#x00627;&#x0062d;&#x0061b; &#x00648;&#x00641;&#x0064a; &#x0062d;&#x00627;&#x00644; &#x00639;&#x0062f;&#x00645; &#x00646;&#x0062c;&#x00627;&#x0062d;&#x00647;&#x00627;&#x0060c; &#x00641;&#x00633;&#x0064a;&#x0062a;&#x00645; &#x00627;&#x00644;&#x00625;&#x00628;&#x00644;&#x00627;&#x0063a; &#x00639;&#x00646; &#x00635;&#x0062f;&#x00648;&#x00631; &#x00646;&#x0062a;&#x0064a;&#x0062c;&#x00629; &#x0063a;&#x0064a;&#x00631; &#x00635;&#x00627;&#x00644;&#x0062d;&#x00629;. &#x00648;&#x00642;&#x0062f; &#x00627;&#x0062d;&#x0062a;&#x00633;&#x00628;&#x00646;&#x00627; &#x00646;&#x00633;&#x00628;&#x00629; &#x00627;&#x00644;&#x00646;&#x0062a;&#x00627;&#x00626;&#x0062c; &#x0063a;&#x0064a;&#x00631; &#x00627;&#x00644;&#x00635;&#x00627;&#x00644;&#x0062d;&#x00629; &#x00627;&#x00644;&#x00635;&#x00627;&#x0062f;&#x00631;&#x00629; &#x00639;&#x00646; &#x00627;&#x00644;&#x0062c;&#x00647;&#x00627;&#x00632; &#x00648;&#x00639;&#x00646; &#x00627;&#x00644;&#x00645;&#x0064f;&#x00634;&#x0063a;&#x00651;&#x00650;&#x00644;. &#x0062a;&#x00645; &#x00627;&#x00633;&#x0062a;&#x0062e;&#x0062f;&#x00627;&#x00645; &#x0062a;&#x0062d;&#x00627;&#x00644;&#x0064a;&#x00644; &#x00627;&#x00644;&#x0062a;&#x0062d;&#x00648;&#x00641;&#x000a0;&#x00644;&#x00627;&#x00633;&#x0062a;&#x00642;&#x00635;&#x00627;&#x00621; &#x00627;&#x00644;&#x00639;&#x00648;&#x00627;&#x00645;&#x00644; &#x00627;&#x00644;&#x00645;&#x00631;&#x0062a;&#x00628;&#x00637;&#x00629; &#x00628;&#x00627;&#x00644;&#x00646;&#x0062a;&#x00627;&#x00626;&#x0062c; &#x0063a;&#x0064a;&#x00631; &#x00627;&#x00644;&#x00635;&#x00627;&#x00644;&#x0062d;&#x00629;. </p></sec><sec><title>&#x00627;&#x00644;&#x00646;&#x0062a;&#x00627;&#x00626;&#x0062c; </title><p>&#x00643;&#x00627;&#x00646;&#x0062a; &#x00647;&#x00646;&#x00627;&#x00643; 4335&#x000a0;&#x00646;&#x0062a;&#x0064a;&#x0062c;&#x00629; &#x00627;&#x0062e;&#x0062a;&#x00628;&#x00627;&#x00631; &#x0063a;&#x0064a;&#x00631; &#x00635;&#x00627;&#x00644;&#x0062d;&#x00629; (&#x00628;&#x00646;&#x00633;&#x00628;&#x00629; &#x0062a;&#x00628;&#x00644;&#x0063a; <styled-content style-type="direction" style="direction:ltr;">13.1%</styled-content>) &#x00639;&#x00628;&#x00631; 39&#x000a0;&#x00645;&#x00648;&#x00642;&#x00639;&#x0064b;&#x00627; &#x00644;&#x00639;&#x0062f;&#x0062f; 58&#x000a0;&#x0062c;&#x00647;&#x00627;&#x00632;&#x0064b;&#x00627; &#x00645;&#x00646; &#x00637;&#x00631;&#x00627;&#x00632; Alere Pima <sup>TM </sup>&#x0200e; &#x00648;180&#x000a0;&#x00645;&#x00646; &#x00627;&#x00644;&#x00645;&#x0064f;&#x00634;&#x0063a;&#x00651;&#x00650;&#x00644;&#x0064a;&#x00646;. &#x00628;&#x00644;&#x0063a;&#x0062a; &#x00646;&#x00633;&#x00628;&#x00629; &#x00645;&#x0062a;&#x00648;&#x00633;&#x00637; &#x00627;&#x00644;&#x00623;&#x0062e;&#x00637;&#x00627;&#x00621; &#x00644;&#x00643;&#x00644; &#x0062c;&#x00647;&#x00627;&#x00632; &#x00648;&#x00645;&#x0064f;&#x00634;&#x0063a;&#x00651;&#x00650;&#x00644; <styled-content style-type="direction" style="direction:ltr;">12.7% </styled-content>(&#x00627;&#x00644;&#x00645;&#x0062f;&#x00649; &#x00627;&#x00644;&#x00631;&#x00628;&#x0064a;&#x00639;&#x0064a;: 10.3&#x02013;19.9) <styled-content style-type="direction" style="direction:ltr;">&#x00648;12.1% </styled-content>(&#x00627;&#x00644;&#x00645;&#x0062f;&#x00649; &#x00627;&#x00644;&#x00631;&#x00628;&#x0064a;&#x00639;&#x0064a;: 7.1&#x02013;19.2)&#x0060c; &#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x0062a;&#x00648;&#x00627;&#x00644;&#x0064a;. &#x00648;&#x00627;&#x0062e;&#x0062a;&#x00644;&#x00641;&#x0062a; &#x00646;&#x00633;&#x00628;&#x00629; &#x00627;&#x00644;&#x00646;&#x0062a;&#x00627;&#x00626;&#x0062c; &#x0063a;&#x0064a;&#x00631; &#x00627;&#x00644;&#x00635;&#x00627;&#x00644;&#x0062d;&#x00629; &#x00628;&#x00634;&#x00643;&#x00644; &#x00648;&#x00627;&#x00633;&#x00639; &#x0062d;&#x00633;&#x00628; &#x00627;&#x00644;&#x00628;&#x00644;&#x0062f; &#x00648;&#x00627;&#x00644;&#x00628;&#x0064a;&#x00626;&#x00629; &#x00648;&#x00627;&#x00644;&#x00645;&#x00633;&#x0062a;&#x0062e;&#x0062f;&#x00645; &#x00648;&#x00627;&#x00644;&#x0062c;&#x00647;&#x00627;&#x00632;. &#x00644;&#x00645; &#x0062a;&#x00643;&#x00646; &#x00627;&#x00644;&#x00623;&#x0062e;&#x00637;&#x00627;&#x00621; &#x00645;&#x00631;&#x0062a;&#x00628;&#x00637;&#x00629; &#x00628;&#x00628;&#x0064a;&#x00626;&#x00629; &#x00627;&#x00644;&#x00627;&#x00633;&#x0062a;&#x0062e;&#x0062f;&#x00627;&#x00645;&#x0060c; &#x00648;&#x00644;&#x00627; &#x0062e;&#x00628;&#x00631;&#x00629; &#x00627;&#x00644;&#x00645;&#x00633;&#x0062a;&#x0062e;&#x0062f;&#x00645;&#x0060c; &#x00648;&#x00644;&#x00627; &#x00639;&#x0062f;&#x0062f; &#x00627;&#x00644;&#x00645;&#x00633;&#x0062a;&#x0062e;&#x0062f;&#x00645;&#x0064a;&#x00646; &#x00641;&#x0064a; &#x00643;&#x00644; &#x0062c;&#x00647;&#x00627;&#x00632;. &#x00648;&#x00643;&#x00627;&#x00646; &#x00627;&#x0062d;&#x0062a;&#x00645;&#x00627;&#x00644; &#x00635;&#x0062f;&#x00648;&#x00631; &#x00627;&#x00644;&#x00623;&#x0062e;&#x00637;&#x00627;&#x00621; &#x00641;&#x0064a; &#x00627;&#x00644;&#x00627;&#x0062e;&#x0062a;&#x00628;&#x00627;&#x00631;&#x00627;&#x0062a; &#x00627;&#x00644;&#x0062a;&#x0064a; &#x00623;&#x0062c;&#x00631;&#x0064a;&#x0062a; &#x00639;&#x00644;&#x00649; &#x00639;&#x0064a;&#x00646;&#x00627;&#x0062a; &#x00627;&#x00644;&#x0062f;&#x00645; &#x00627;&#x00644;&#x00634;&#x00639;&#x00631;&#x0064a; &#x00648;&#x00627;&#x00631;&#x0062f;&#x0064b;&#x00627; &#x00628;&#x0062f;&#x00631;&#x0062c;&#x00629; &#x00623;&#x00642;&#x00644; &#x00643;&#x0062b;&#x0064a;&#x00631;&#x0064b;&#x00627; &#x00628;&#x00627;&#x00644;&#x00645;&#x00642;&#x00627;&#x00631;&#x00646;&#x00629; &#x00645;&#x00639; &#x00639;&#x0064a;&#x00646;&#x00627;&#x0062a; &#x00627;&#x00644;&#x0062f;&#x00645; &#x00627;&#x00644;&#x00643;&#x00627;&#x00645;&#x00644; &#x00627;&#x00644;&#x00648;&#x00631;&#x0064a;&#x0062f;&#x0064a;. </p></sec><sec><title>&#x00627;&#x00644;&#x00627;&#x00633;&#x0062a;&#x00646;&#x0062a;&#x00627;&#x0062c; </title><p>&#x00623;&#x00635;&#x0062f;&#x00631; &#x0062c;&#x00647;&#x00627;&#x00632; &#x00627;&#x00644;&#x0062a;&#x0062d;&#x00644;&#x0064a;&#x00644; Alere Pima CD4+&#x0200e; &#x00646;&#x00633;&#x00628;&#x00629; &#x00639;&#x00627;&#x00644;&#x0064a;&#x00629; &#x00645;&#x00646; &#x00646;&#x0062a;&#x00627;&#x00626;&#x0062c; &#x00627;&#x00644;&#x00627;&#x0062e;&#x0062a;&#x00628;&#x00627;&#x00631; &#x0063a;&#x0064a;&#x00631; &#x00627;&#x00644;&#x00635;&#x00627;&#x00644;&#x0062d;&#x00629;&#x0060c; &#x00639;&#x00628;&#x00631; &#x00628;&#x00644;&#x0062f;&#x00627;&#x00646; &#x00648;&#x00628;&#x0064a;&#x00626;&#x00627;&#x0062a; &#x00627;&#x00633;&#x0062a;&#x0062e;&#x0062f;&#x00627;&#x00645; &#x00648;&#x00645;&#x00633;&#x0062a;&#x0062e;&#x0062f;&#x00645;&#x0064a;&#x00646; &#x00645;&#x0062e;&#x0062a;&#x00644;&#x00641;&#x0064a;&#x00646;. &#x0064a;&#x00645;&#x00643;&#x00646; &#x00639;&#x00632;&#x00648; &#x00645;&#x00639;&#x00638;&#x00645; &#x00631;&#x00645;&#x00648;&#x00632; &#x00627;&#x00644;&#x0062e;&#x00637;&#x00623; &#x00625;&#x00644;&#x00649; &#x00627;&#x00644;&#x00645;&#x0064f;&#x00634;&#x0063a;&#x00651;&#x00650;&#x00644;&#x0060c; &#x00648;&#x00644;&#x00643;&#x00646; &#x0062b;&#x00628;&#x0062a; &#x00623;&#x00646;&#x00647; &#x00645;&#x00646; &#x00627;&#x00644;&#x00635;&#x00639;&#x00628; &#x0062a;&#x0062d;&#x0062f;&#x0064a;&#x0062f; &#x00627;&#x00644;&#x00623;&#x00633;&#x00628;&#x00627;&#x00628; &#x00627;&#x00644;&#x0062d;&#x00642;&#x0064a;&#x00642;&#x0064a;&#x00629;. &#x00647;&#x00646;&#x00627;&#x00643; &#x0062d;&#x00627;&#x0062c;&#x00629; &#x00644;&#x00645;&#x00631;&#x00627;&#x00639;&#x00627;&#x00629; &#x00627;&#x00644;&#x00646;&#x0062a;&#x00627;&#x00626;&#x0062c; &#x0063a;&#x0064a;&#x00631; &#x00627;&#x00644;&#x00635;&#x00627;&#x00644;&#x0062d;&#x00629; &#x00641;&#x0064a; &#x0062a;&#x00643;&#x00627;&#x00644;&#x0064a;&#x00641; &#x00627;&#x00644;&#x0062a;&#x00646;&#x00641;&#x0064a;&#x00630; &#x00648;&#x00627;&#x00644;&#x0062a;&#x00634;&#x0063a;&#x0064a;&#x00644; &#x00644;&#x00627;&#x0062e;&#x0062a;&#x00628;&#x00627;&#x00631; &#x0062e;&#x00644;&#x00627;&#x0064a;&#x00627; &#x00627;&#x00644;&#x00644;&#x00645;&#x00641;&#x00627;&#x00648;&#x0064a;&#x00627;&#x0062a; &#x00627;&#x00644;&#x0062a;&#x00627;&#x00626;&#x0064a;&#x00629; CD4+&#x0200e; &#x00627;&#x00644;&#x00631;&#x00648;&#x0062a;&#x0064a;&#x00646;&#x0064a;. </p></sec></trans-abstract><trans-abstract xml:lang="zh"><title>&#x06458;&#x08981;</title><sec><title>&#x076ee;&#x07684;</title><p>&#x065e8;&#x05728;&#x08bc4;&#x04f30;&#x07531;&#x065e0;&#x056fd;&#x0754c;&#x0533b;&#x0751f;&#x07ec4;&#x07ec7;&#x000a0; (MSF) &#x000a0;&#x07528;&#x04e8e;&#x05b9e;&#x05730;&#x09879;&#x076ee;&#x07684;&#x000a0;CD4+&#x000a0;T-&#x06dcb;&#x05df4;&#x07ec6;&#x05206;&#x06790;&#x05668;&#x04ea7;&#x0751f;&#x065e0;&#x06548;&#x07ed3;&#x0679c;&#x07684;&#x06bd4;&#x04f8b;&#x0ff0c;&#x05e76;&#x0786e;&#x08ba4;&#x04e0e;&#x065e0;&#x06548;&#x07ed3;&#x0679c;&#x076f8;&#x05173;&#x07684;&#x056e0;&#x07d20;&#x03002;</p></sec><sec><title>&#x065b9;&#x06cd5;</title><p>&#x06211;&#x04eec;&#x04ece;&#x000a0;9&#x000a0;&#x04e2a;&#x056fd;&#x05bb6;&#x07684;&#x000a0;39&#x000a0;&#x04e2a;&#x0533b;&#x07597;&#x070b9;&#x04e2d;&#x083b7;&#x053d6;&#x04e86;&#x000a0;25&#x02009;616&#x000a0;&#x09879;&#x05728;&#x000a0;2011&#x000a0;&#x05e74;&#x081f3;&#x000a0;2013&#x000a0;&#x05e74;&#x0671f;&#x095f4;&#x05173;&#x04e8e;&#x000a0;CD4+&#x000a0;T-&#x06dcb;&#x05df4;&#x07ec6;&#x080de;&#x07684;&#x06d4b;&#x08bd5;&#x07ed3;&#x0679c;&#x03002;&#x0901a;&#x08fc7;&#x08c03;&#x067e5;&#x095ee;&#x05377;&#x083b7;&#x05f97;&#x04e86;&#x05173;&#x04e8e;&#x073af;&#x05883;&#x03001;&#x07528;&#x06237;&#x03001;&#x057f9;&#x08bad;&#x03001;&#x091c7;&#x06837;&#x06280;&#x0672f;&#x0548c;&#x08bbe;&#x05907;&#x07ef4;&#x04fee;&#x08bb0;&#x05f55;&#x07684;&#x04fe1;&#x0606f;&#x03002; &#x05206;&#x06790;&#x05668;&#x04f1a;&#x08fdb;&#x0884c;&#x04e00;&#x07cfb;&#x05217;&#x068c0;&#x067e5;&#x0ff0c;&#x04ee5;&#x0786e;&#x04fdd;&#x05206;&#x06790;&#x07684;&#x06240;&#x06709;&#x06b65;&#x09aa4;&#x090fd;&#x080fd;&#x06210;&#x0529f;&#x05b8c;&#x06210;&#x0ff1b;&#x05982;&#x0679c;&#x04e0d;&#x080fd;&#x0ff0c;&#x05219;&#x062a5;&#x0544a;&#x065e0;&#x06548;&#x07ed3;&#x0679c;&#x03002; &#x06211;&#x04eec;&#x0901a;&#x08fc7;&#x08bbe;&#x05907;&#x0548c;&#x064cd;&#x04f5c;&#x05458;&#x08ba1;&#x07b97;&#x04e86;&#x065e0;&#x06548;&#x07ed3;&#x0679c;&#x07684;&#x06bd4;&#x04f8b;&#x03002; &#x056de;&#x05f52;&#x05206;&#x06790;&#x07528;&#x04e8e;&#x08c03;&#x067e5;&#x04e0e;&#x065e0;&#x06548;&#x07ed3;&#x0679c;&#x06709;&#x05173;&#x07684;&#x056e0;&#x07d20;&#x03002;</p></sec><sec><title>&#x07ed3;&#x0679c;</title><p>&#x05728;&#x000a0;34&#x000a0;&#x04e2a;&#x0533b;&#x07597;&#x070b9;&#x07684;&#x000a0;58&#x000a0;&#x04e2a;&#x000a0;Alere&#x000a0;Pima<sup>TM</sup>&#x000a0;&#x08bbe;&#x05907;&#x0548c;&#x000a0;180&#x000a0;&#x0540d;&#x064cd;&#x04f5c;&#x05458;&#x04e2d;&#x0ff0c;&#x051fa;&#x073b0;&#x04e86;&#x000a0;3354&#x000a0;&#x09879;&#x065e0;&#x06548;&#x06d4b;&#x08bd5;&#x07ed3;&#x0679c;&#x000a0; (13.1%)&#x03002; &#x06bcf;&#x04e2a;&#x08bbe;&#x05907;&#x0548c;&#x064cd;&#x04f5c;&#x05458;&#x07684;&#x09519;&#x08bef;&#x06bd4;&#x04f8b;&#x04e2d;&#x0503c;&#x05206;&#x0522b;&#x04e3a;&#x000a0;12.7%&#x0ff08;&#x056db;&#x05206;&#x04f4d;&#x05dee;&#x0ff0c;IQR&#x0ff1a; 10.3&#x02013;19.9) &#x000a0;&#x0548c;&#x000a0;12.1% (IQR: 7.1&#x02013;19.2)&#x03002; &#x065e0;&#x06548;&#x07ed3;&#x0679c;&#x07684;&#x06bd4;&#x04f8b;&#x056e0;&#x056fd;&#x05bb6;&#x03001;&#x073af;&#x05883;&#x03001;&#x07528;&#x06237;&#x0548c;&#x08bbe;&#x05907;&#x0800c;&#x05f02;&#x03002; &#x06bcf;&#x04e2a;&#x08bbe;&#x05907;&#x07684;&#x09519;&#x08bef;&#x04e0e;&#x073af;&#x05883;&#x03001;&#x07528;&#x06237;&#x07ecf;&#x09a8c;&#x06216;&#x07528;&#x06237;&#x06570;&#x091cf;&#x065e0;&#x05173;&#x03002; &#x04e0e;&#x09759;&#x08109;&#x05168;&#x08840;&#x076f8;&#x06bd4;&#x0ff0c;&#x05173;&#x04e8e;&#x06bdb;&#x07ec6;&#x07ba1;&#x08840;&#x06837;&#x07684;&#x06d4b;&#x08bd5;&#x051fa;&#x073b0;&#x09519;&#x08bef;&#x07684;&#x053ef;&#x0884c;&#x06027;&#x066f4;&#x04f4e;&#x03002;</p></sec><sec><title>&#x07ed3;&#x08bba;</title><p>Alere&#x000a0;Pima&#x000a0;CD4+&#x000a0;&#x05206;&#x06790;&#x05668;&#x05728;&#x04e0d;&#x0540c;&#x056fd;&#x05bb6;&#x03001;&#x073af;&#x05883;&#x0548c;&#x07528;&#x06237;&#x04e2d;&#x051fa;&#x073b0;&#x065e0;&#x06548;&#x06d4b;&#x08bd5;&#x07ed3;&#x0679c;&#x07684;&#x06bd4;&#x04f8b;&#x05f88;&#x09ad8;&#x03002; &#x05927;&#x0591a;&#x06570;&#x09519;&#x08bef;&#x04ee3;&#x07801;&#x05f52;&#x056e0;&#x04e8e;&#x064cd;&#x04f5c;&#x05458;&#x0ff0c;&#x04f46;&#x0662f;&#x05f88;&#x096be;&#x0786e;&#x08ba4;&#x051fa;&#x0786e;&#x05207;&#x07684;&#x0539f;&#x056e0;&#x03002; &#x065e0;&#x06548;&#x07ed3;&#x0679c;&#x09700;&#x05728;&#x000a0;CD4+&#x000a0;T-&#x06dcb;&#x05df4;&#x07ec6;&#x080de;&#x05e38;&#x089c4;&#x06d4b;&#x08bd5;&#x07684;&#x05b9e;&#x065bd;&#x0548c;&#x064cd;&#x04f5c;&#x06210;&#x0672c;&#x04e2d;&#x04f5c;&#x04e3a;&#x056e0;&#x07d20;&#x07eb3;&#x05165;&#x08003;&#x08651;&#x03002;</p></sec></trans-abstract><trans-abstract xml:lang="ru"><title>&#x00420;&#x00435;&#x00437;&#x0044e;&#x0043c;&#x00435;</title><sec><title>&#x00426;&#x00435;&#x0043b;&#x0044c;</title><p>&#x0041e;&#x00446;&#x00435;&#x0043d;&#x00438;&#x00442;&#x0044c; &#x00434;&#x0043e;&#x0043b;&#x0044e; &#x0043d;&#x00435;&#x00434;&#x00435;&#x00439;&#x00441;&#x00442;&#x00432;&#x00438;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x0044b;&#x00445; &#x00440;&#x00435;&#x00437;&#x00443;&#x0043b;&#x0044c;&#x00442;&#x00430;&#x00442;&#x0043e;&#x00432;, &#x00432;&#x0044b;&#x00434;&#x00430;&#x00432;&#x00430;&#x00435;&#x0043c;&#x0044b;&#x00445; &#x00430;&#x0043d;&#x00430;&#x0043b;&#x00438;&#x00437;&#x00430;&#x00442;&#x0043e;&#x00440;&#x0043e;&#x0043c; &#x0043a;&#x0043e;&#x0043b;&#x00438;&#x00447;&#x00435;&#x00441;&#x00442;&#x00432;&#x00430; CD4+ T-&#x0043b;&#x00438;&#x0043c;&#x00444;&#x0043e;&#x00446;&#x00438;&#x00442;&#x0043e;&#x00432; &#x00432; &#x0043f;&#x0043e;&#x0043b;&#x00435;&#x00432;&#x0044b;&#x00445; &#x00443;&#x00441;&#x0043b;&#x0043e;&#x00432;&#x00438;&#x0044f;&#x00445; &#x00432; &#x00440;&#x00430;&#x0043c;&#x0043a;&#x00430;&#x00445; &#x0043f;&#x00440;&#x0043e;&#x00435;&#x0043a;&#x00442;&#x0043e;&#x00432; &#x0043e;&#x00440;&#x00433;&#x00430;&#x0043d;&#x00438;&#x00437;&#x00430;&#x00446;&#x00438;&#x00438; &#x000ab;&#x00412;&#x00440;&#x00430;&#x00447;&#x00438; &#x00431;&#x00435;&#x00437; &#x00433;&#x00440;&#x00430;&#x0043d;&#x00438;&#x00446;&#x000bb; (M&#x000e9;decins Sans Fronti&#x000e8;res, MSF), &#x00438; &#x00432;&#x0044b;&#x0044f;&#x00432;&#x00438;&#x00442;&#x0044c; &#x00444;&#x00430;&#x0043a;&#x00442;&#x0043e;&#x00440;&#x0044b;, &#x00432;&#x0044b;&#x00437;&#x0044b;&#x00432;&#x00430;&#x0044e;&#x00449;&#x00438;&#x00435; &#x0043d;&#x00435;&#x00434;&#x00435;&#x00439;&#x00441;&#x00442;&#x00432;&#x00438;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x0044b;&#x00435; &#x00440;&#x00435;&#x00437;&#x00443;&#x0043b;&#x0044c;&#x00442;&#x00430;&#x00442;&#x0044b;.</p></sec><sec><title>&#x0041c;&#x00435;&#x00442;&#x0043e;&#x00434;&#x0044b;</title><p>&#x0041c;&#x0044b; &#x00441;&#x00440;&#x00430;&#x00432;&#x0043d;&#x00438;&#x0043b;&#x00438; 25&#x000a0;616&#x000a0;&#x00440;&#x00435;&#x00437;&#x00443;&#x0043b;&#x0044c;&#x00442;&#x00430;&#x00442;&#x0043e;&#x00432; &#x0043e;&#x0043f;&#x00440;&#x00435;&#x00434;&#x00435;&#x0043b;&#x00435;&#x0043d;&#x00438;&#x0044f; CD4+ T-&#x0043b;&#x00438;&#x0043c;&#x00444;&#x0043e;&#x00446;&#x00438;&#x00442;&#x0043e;&#x00432; &#x00432; 39&#x000a0;&#x0043c;&#x00435;&#x00434;&#x00438;&#x00446;&#x00438;&#x0043d;&#x00441;&#x0043a;&#x00438;&#x00445; &#x00443;&#x00447;&#x00440;&#x00435;&#x00436;&#x00434;&#x00435;&#x0043d;&#x00438;&#x0044f;&#x00445; &#x00438;&#x00437; &#x00434;&#x00435;&#x00432;&#x0044f;&#x00442;&#x00438; &#x00441;&#x00442;&#x00440;&#x00430;&#x0043d; &#x00437;&#x00430; &#x00434;&#x00432;&#x00430; &#x00433;&#x0043e;&#x00434;&#x00430; (&#x00441; 2011 &#x0043f;&#x0043e; 2013&#x000a0;&#x00433;&#x0043e;&#x00434;). &#x00418;&#x0043d;&#x00444;&#x0043e;&#x00440;&#x0043c;&#x00430;&#x00446;&#x00438;&#x0044f; &#x0043e;&#x00442;&#x0043d;&#x0043e;&#x00441;&#x00438;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x0043e; &#x00443;&#x00441;&#x0043b;&#x0043e;&#x00432;&#x00438;&#x00439; &#x0043f;&#x00440;&#x0043e;&#x00432;&#x00435;&#x00434;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00430;&#x0043d;&#x00430;&#x0043b;&#x00438;&#x00437;&#x00430;, &#x00430; &#x00442;&#x00430;&#x0043a;&#x00436;&#x00435; &#x00441;&#x00432;&#x00435;&#x00434;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x0043e; &#x0043f;&#x0043e;&#x0043b;&#x0044c;&#x00437;&#x0043e;&#x00432;&#x00430;&#x00442;&#x00435;&#x0043b;&#x00435;, &#x00435;&#x00433;&#x0043e; &#x0043e;&#x00431;&#x00443;&#x00447;&#x00435;&#x0043d;&#x00438;&#x00438;, &#x0043c;&#x00435;&#x00442;&#x0043e;&#x00434;&#x00438;&#x0043a;&#x00435; &#x0043e;&#x00442;&#x00431;&#x0043e;&#x00440;&#x00430; &#x0043f;&#x00440;&#x0043e;&#x00431; &#x00438; &#x00438;&#x00441;&#x00442;&#x0043e;&#x00440;&#x00438;&#x00438; &#x00440;&#x00435;&#x0043c;&#x0043e;&#x0043d;&#x00442;&#x00430; &#x00438;&#x00437;&#x0043c;&#x00435;&#x00440;&#x00438;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x0043e;&#x00433;&#x0043e; &#x0043f;&#x00440;&#x00438;&#x00431;&#x0043e;&#x00440;&#x00430; &#x00431;&#x0044b;&#x0043b;&#x00430; &#x0043f;&#x0043e;&#x0043b;&#x00443;&#x00447;&#x00435;&#x0043d;&#x00430; &#x00432; &#x00445;&#x0043e;&#x00434;&#x00435; &#x00430;&#x0043d;&#x0043a;&#x00435;&#x00442;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x0044f;. &#x00410;&#x0043d;&#x00430;&#x0043b;&#x00438;&#x00437;&#x00430;&#x00442;&#x0043e;&#x00440; &#x00432;&#x0044b;&#x0043f;&#x0043e;&#x0043b;&#x0043d;&#x0044f;&#x00435;&#x00442; &#x00440;&#x0044f;&#x00434; &#x0043f;&#x00440;&#x0043e;&#x00432;&#x00435;&#x00440;&#x0043e;&#x0043a; &#x00434;&#x0043b;&#x0044f; &#x00442;&#x0043e;&#x00433;&#x0043e;, &#x00447;&#x00442;&#x0043e;&#x00431;&#x0044b; &#x00443;&#x00434;&#x0043e;&#x00441;&#x00442;&#x0043e;&#x00432;&#x00435;&#x00440;&#x00438;&#x00442;&#x0044c;&#x00441;&#x0044f; &#x00432; &#x00443;&#x00441;&#x0043f;&#x00435;&#x00448;&#x0043d;&#x0043e;&#x0043c; &#x00432;&#x0044b;&#x0043f;&#x0043e;&#x0043b;&#x0043d;&#x00435;&#x0043d;&#x00438;&#x00438; &#x00432;&#x00441;&#x00435;&#x00445; &#x0044d;&#x00442;&#x00430;&#x0043f;&#x0043e;&#x00432; &#x00430;&#x0043d;&#x00430;&#x0043b;&#x00438;&#x00437;&#x00430;. &#x00412; &#x0043f;&#x00440;&#x0043e;&#x00442;&#x00438;&#x00432;&#x0043d;&#x0043e;&#x0043c; &#x00441;&#x0043b;&#x00443;&#x00447;&#x00430;&#x00435; &#x00432;&#x0044b;&#x00434;&#x00430;&#x00435;&#x00442;&#x00441;&#x0044f; &#x00441;&#x0043e;&#x0043e;&#x00431;&#x00449;&#x00435;&#x0043d;&#x00438;&#x00435; &#x0043e; &#x0043d;&#x00435;&#x00434;&#x00435;&#x00439;&#x00441;&#x00442;&#x00432;&#x00438;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x0043e;&#x0043c; &#x00440;&#x00435;&#x00437;&#x00443;&#x0043b;&#x0044c;&#x00442;&#x00430;&#x00442;&#x00435;. &#x0041c;&#x0044b; &#x00440;&#x00430;&#x00441;&#x00441;&#x00447;&#x00438;&#x00442;&#x00430;&#x0043b;&#x00438; &#x00434;&#x0043e;&#x0043b;&#x0044e; &#x0043d;&#x00435;&#x00434;&#x00435;&#x00439;&#x00441;&#x00442;&#x00432;&#x00438;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x0044b;&#x00445; &#x00440;&#x00435;&#x00437;&#x00443;&#x0043b;&#x0044c;&#x00442;&#x00430;&#x00442;&#x0043e;&#x00432; &#x00434;&#x0043b;&#x0044f; &#x0043a;&#x00430;&#x00436;&#x00434;&#x0043e;&#x00433;&#x0043e; &#x00443;&#x00441;&#x00442;&#x00440;&#x0043e;&#x00439;&#x00441;&#x00442;&#x00432;&#x00430; &#x00438; &#x0043a;&#x00430;&#x00436;&#x00434;&#x0043e;&#x00433;&#x0043e; &#x0043e;&#x0043f;&#x00435;&#x00440;&#x00430;&#x00442;&#x0043e;&#x00440;&#x00430;. &#x00414;&#x0043b;&#x0044f; &#x00438;&#x00437;&#x00443;&#x00447;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00444;&#x00430;&#x0043a;&#x00442;&#x0043e;&#x00440;&#x0043e;&#x00432;, &#x00432;&#x0044b;&#x00437;&#x0044b;&#x00432;&#x00430;&#x0044e;&#x00449;&#x00438;&#x00445; &#x0043d;&#x00435;&#x00434;&#x00435;&#x00439;&#x00441;&#x00442;&#x00432;&#x00438;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x0044b;&#x00435; &#x00440;&#x00435;&#x00437;&#x00443;&#x0043b;&#x0044c;&#x00442;&#x00430;&#x00442;&#x0044b;, &#x00431;&#x0044b;&#x0043b; &#x0043f;&#x00440;&#x0043e;&#x00432;&#x00435;&#x00434;&#x00435;&#x0043d; &#x00440;&#x00435;&#x00433;&#x00440;&#x00435;&#x00441;&#x00441;&#x00438;&#x0043e;&#x0043d;&#x0043d;&#x0044b;&#x00439; &#x00430;&#x0043d;&#x00430;&#x0043b;&#x00438;&#x00437;.</p></sec><sec><title>&#x00420;&#x00435;&#x00437;&#x00443;&#x0043b;&#x0044c;&#x00442;&#x00430;&#x00442;&#x0044b;</title><p>&#x00412; 39 &#x00443;&#x00447;&#x00440;&#x00435;&#x00436;&#x00434;&#x00435;&#x0043d;&#x00438;&#x0044f;&#x00445;, &#x00433;&#x00434;&#x00435; &#x00438;&#x00441;&#x0043f;&#x0043e;&#x0043b;&#x0044c;&#x00437;&#x0043e;&#x00432;&#x00430;&#x0043b;&#x0043e;&#x00441;&#x0044c; 58 &#x00443;&#x00441;&#x00442;&#x00440;&#x0043e;&#x00439;&#x00441;&#x00442;&#x00432; &#x00441;&#x00435;&#x00440;&#x00438;&#x00438; Alere Pima<sup>TM</sup> &#x00438; &#x00440;&#x00430;&#x00431;&#x0043e;&#x00442;&#x00430;&#x0043b;&#x0043e; 180&#x000a0;&#x0043e;&#x0043f;&#x00435;&#x00440;&#x00430;&#x00442;&#x0043e;&#x00440;&#x0043e;&#x00432;, &#x00431;&#x0044b;&#x0043b;&#x0043e; &#x00432;&#x0044b;&#x0044f;&#x00432;&#x0043b;&#x00435;&#x0043d;&#x0043e; 3354&#x000a0;&#x0043d;&#x00435;&#x00434;&#x00435;&#x00439;&#x00441;&#x00442;&#x00432;&#x00438;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x0044b;&#x00445; &#x00440;&#x00435;&#x00437;&#x00443;&#x0043b;&#x0044c;&#x00442;&#x00430;&#x00442;&#x00430; &#x00438;&#x00441;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x00439; (13,1%). &#x0041c;&#x00435;&#x00434;&#x00438;&#x00430;&#x0043d;&#x0043d;&#x00430;&#x0044f; &#x00434;&#x0043e;&#x0043b;&#x0044f; &#x0043e;&#x00448;&#x00438;&#x00431;&#x0043e;&#x0043a; &#x00432; &#x0043f;&#x00435;&#x00440;&#x00435;&#x00441;&#x00447;&#x00435;&#x00442;&#x00435; &#x0043d;&#x00430; &#x00443;&#x00441;&#x00442;&#x00440;&#x0043e;&#x00439;&#x00441;&#x00442;&#x00432;&#x0043e; &#x00438; &#x0043e;&#x0043f;&#x00435;&#x00440;&#x00430;&#x00442;&#x0043e;&#x00440;&#x00430; &#x00441;&#x0043e;&#x00441;&#x00442;&#x00430;&#x00432;&#x00438;&#x0043b;&#x00430; 12,7% (&#x0043c;&#x00435;&#x00436;&#x0043a;&#x00432;&#x00430;&#x00440;&#x00442;&#x00438;&#x0043b;&#x0044c;&#x0043d;&#x0044b;&#x00439; &#x00440;&#x00430;&#x00437;&#x0043c;&#x00430;&#x00445;, &#x0041c;&#x0041a;&#x00420;: 10,3&#x02013;19,9) &#x00438; 12,1% (&#x0041c;&#x0041a;&#x00420;: 7,1&#x02013;19,2) &#x00441;&#x0043e;&#x0043e;&#x00442;&#x00432;&#x00435;&#x00442;&#x00441;&#x00442;&#x00432;&#x00435;&#x0043d;&#x0043d;&#x0043e;. &#x00414;&#x0043e;&#x0043b;&#x0044f; &#x0043d;&#x00435;&#x00434;&#x00435;&#x00439;&#x00441;&#x00442;&#x00432;&#x00438;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x0044b;&#x00445; &#x00440;&#x00435;&#x00437;&#x00443;&#x0043b;&#x0044c;&#x00442;&#x00430;&#x00442;&#x0043e;&#x00432; &#x00432; &#x00437;&#x0043d;&#x00430;&#x00447;&#x00438;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x0043e;&#x00439; &#x0043c;&#x00435;&#x00440;&#x00435; &#x00432;&#x00430;&#x00440;&#x0044c;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x0043b;&#x00430;&#x00441;&#x0044c; &#x00432; &#x00437;&#x00430;&#x00432;&#x00438;&#x00441;&#x00438;&#x0043c;&#x0043e;&#x00441;&#x00442;&#x00438; &#x0043e;&#x00442; &#x00441;&#x00442;&#x00440;&#x00430;&#x0043d;&#x0044b;, &#x00443;&#x00441;&#x0043b;&#x0043e;&#x00432;&#x00438;&#x00439; &#x0043f;&#x00440;&#x0043e;&#x00432;&#x00435;&#x00434;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00430;&#x0043d;&#x00430;&#x0043b;&#x00438;&#x00437;&#x00430;, &#x0043f;&#x0043e;&#x0043b;&#x0044c;&#x00437;&#x0043e;&#x00432;&#x00430;&#x00442;&#x00435;&#x0043b;&#x0044f; &#x00438; &#x00443;&#x00441;&#x00442;&#x00440;&#x0043e;&#x00439;&#x00441;&#x00442;&#x00432;&#x00430;. &#x0041e;&#x00448;&#x00438;&#x00431;&#x0043a;&#x00438; &#x0043d;&#x00435; &#x00431;&#x0044b;&#x0043b;&#x00438; &#x00441;&#x00432;&#x0044f;&#x00437;&#x00430;&#x0043d;&#x0044b; &#x00441; &#x00443;&#x00441;&#x0043b;&#x0043e;&#x00432;&#x00438;&#x0044f;&#x0043c;&#x00438; &#x0043f;&#x00440;&#x0043e;&#x00432;&#x00435;&#x00434;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00430;&#x0043d;&#x00430;&#x0043b;&#x00438;&#x00437;&#x00430;, &#x0043e;&#x0043f;&#x0044b;&#x00442;&#x0043e;&#x0043c; &#x0043f;&#x0043e;&#x0043b;&#x0044c;&#x00437;&#x0043e;&#x00432;&#x00430;&#x00442;&#x00435;&#x0043b;&#x0044f; &#x00438;&#x0043b;&#x00438; &#x0043a;&#x0043e;&#x0043b;&#x00438;&#x00447;&#x00435;&#x00441;&#x00442;&#x00432;&#x0043e;&#x0043c; &#x0043f;&#x0043e;&#x0043b;&#x0044c;&#x00437;&#x0043e;&#x00432;&#x00430;&#x00442;&#x00435;&#x0043b;&#x00435;&#x00439; &#x00434;&#x0043b;&#x0044f; &#x0043e;&#x00434;&#x0043d;&#x0043e;&#x00433;&#x0043e; &#x00438; &#x00442;&#x0043e;&#x00433;&#x0043e; &#x00436;&#x00435; &#x00443;&#x00441;&#x00442;&#x00440;&#x0043e;&#x00439;&#x00441;&#x00442;&#x00432;&#x00430;. &#x00415;&#x00441;&#x0043b;&#x00438; &#x00434;&#x0043b;&#x0044f; &#x00430;&#x0043d;&#x00430;&#x0043b;&#x00438;&#x00437;&#x00430; &#x00438;&#x00441;&#x0043f;&#x0043e;&#x0043b;&#x0044c;&#x00437;&#x0043e;&#x00432;&#x00430;&#x0043b;&#x00430;&#x00441;&#x0044c; &#x0043a;&#x00440;&#x0043e;&#x00432;&#x0044c; &#x00438;&#x00437; &#x0043f;&#x00430;&#x0043b;&#x0044c;&#x00446;&#x00430;, &#x0043f;&#x0043e;&#x0044f;&#x00432;&#x0043b;&#x00435;&#x0043d;&#x00438;&#x00435; &#x0043d;&#x00435;&#x00434;&#x00435;&#x00439;&#x00441;&#x00442;&#x00432;&#x00438;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x0044b;&#x00445; &#x00430;&#x0043d;&#x00430;&#x0043b;&#x00438;&#x00437;&#x0043e;&#x00432; &#x00431;&#x0044b;&#x0043b;&#x0043e; &#x00437;&#x0043d;&#x00430;&#x00447;&#x00438;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x0043e; &#x0043c;&#x00435;&#x0043d;&#x00435;&#x00435; &#x00432;&#x00435;&#x00440;&#x0043e;&#x0044f;&#x00442;&#x0043d;&#x0043e;, &#x00447;&#x00435;&#x0043c; &#x0043f;&#x00440;&#x00438; &#x00438;&#x00441;&#x0043f;&#x0043e;&#x0043b;&#x0044c;&#x00437;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x00438; &#x0043f;&#x00440;&#x0043e;&#x00431; &#x00432;&#x00435;&#x0043d;&#x0043e;&#x00437;&#x0043d;&#x0043e;&#x00439; &#x0043a;&#x00440;&#x0043e;&#x00432;&#x00438;.</p></sec><sec><title>&#x00412;&#x0044b;&#x00432;&#x0043e;&#x00434;</title><p>&#x00410;&#x0043d;&#x00430;&#x0043b;&#x00438;&#x00437;&#x00430;&#x00442;&#x0043e;&#x00440; Alere Pima CD4+ &#x00432;&#x0044b;&#x00434;&#x00430;&#x00435;&#x00442; &#x00437;&#x0043d;&#x00430;&#x00447;&#x00438;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x0044b;&#x00439; &#x0043f;&#x00440;&#x0043e;&#x00446;&#x00435;&#x0043d;&#x00442; &#x0043d;&#x00435;&#x00434;&#x00435;&#x00439;&#x00441;&#x00442;&#x00432;&#x00438;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x0044b;&#x00445; &#x00440;&#x00435;&#x00437;&#x00443;&#x0043b;&#x0044c;&#x00442;&#x00430;&#x00442;&#x0043e;&#x00432; &#x00432; &#x00437;&#x00430;&#x00432;&#x00438;&#x00441;&#x00438;&#x0043c;&#x0043e;&#x00441;&#x00442;&#x00438; &#x0043e;&#x00442; &#x00441;&#x00442;&#x00440;&#x00430;&#x0043d;&#x0044b;, &#x00443;&#x00441;&#x0043b;&#x0043e;&#x00432;&#x00438;&#x00439; &#x0043f;&#x00440;&#x0043e;&#x00432;&#x00435;&#x00434;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00430;&#x0043d;&#x00430;&#x0043b;&#x00438;&#x00437;&#x00430; &#x00438; &#x00443;&#x00447;&#x00430;&#x00441;&#x00442;&#x00438;&#x0044f; &#x00440;&#x00430;&#x00437;&#x0043b;&#x00438;&#x00447;&#x0043d;&#x0044b;&#x00445; &#x0043e;&#x0043f;&#x00435;&#x00440;&#x00430;&#x00442;&#x0043e;&#x00440;&#x0043e;&#x00432;. &#x00412;&#x0043e;&#x00437;&#x0043d;&#x00438;&#x0043a;&#x0043d;&#x0043e;&#x00432;&#x00435;&#x0043d;&#x00438;&#x00435; &#x00431;&#x0043e;&#x0043b;&#x0044c;&#x00448;&#x00438;&#x0043d;&#x00441;&#x00442;&#x00432;&#x00430; &#x0043e;&#x00448;&#x00438;&#x00431;&#x0043e;&#x0043a; &#x00441;&#x00432;&#x0044f;&#x00437;&#x00430;&#x0043d;&#x0043e; &#x00441; &#x00440;&#x00430;&#x00431;&#x0043e;&#x00442;&#x0043e;&#x00439; &#x0043e;&#x0043f;&#x00435;&#x00440;&#x00430;&#x00442;&#x0043e;&#x00440;&#x0043e;&#x00432;, &#x0043d;&#x0043e; &#x0043e;&#x0043f;&#x00440;&#x00435;&#x00434;&#x00435;&#x0043b;&#x00438;&#x00442;&#x0044c; &#x00442;&#x0043e;&#x00447;&#x0043d;&#x00443;&#x0044e; &#x0043f;&#x00440;&#x00438;&#x00447;&#x00438;&#x0043d;&#x00443; &#x0043e;&#x0043a;&#x00430;&#x00437;&#x00430;&#x0043b;&#x0043e;&#x00441;&#x0044c; &#x00437;&#x00430;&#x00442;&#x00440;&#x00443;&#x00434;&#x0043d;&#x00438;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x0043e;. &#x0041d;&#x00435;&#x00434;&#x00435;&#x00439;&#x00441;&#x00442;&#x00432;&#x00438;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x0044b;&#x00435; &#x00440;&#x00435;&#x00437;&#x00443;&#x0043b;&#x0044c;&#x00442;&#x00430;&#x00442;&#x0044b; &#x00441;&#x0043b;&#x00435;&#x00434;&#x00443;&#x00435;&#x00442; &#x00443;&#x00447;&#x00438;&#x00442;&#x0044b;&#x00432;&#x00430;&#x00442;&#x0044c; &#x0043f;&#x00440;&#x00438; &#x0043e;&#x0043f;&#x00440;&#x00435;&#x00434;&#x00435;&#x0043b;&#x00435;&#x0043d;&#x00438;&#x00438; &#x00440;&#x00430;&#x00441;&#x00445;&#x0043e;&#x00434;&#x0043e;&#x00432; &#x0043d;&#x00430; &#x00432;&#x0043d;&#x00435;&#x00434;&#x00440;&#x00435;&#x0043d;&#x00438;&#x00435; &#x00438; &#x0043e;&#x00441;&#x00443;&#x00449;&#x00435;&#x00441;&#x00442;&#x00432;&#x0043b;&#x00435;&#x0043d;&#x00438;&#x00435; &#x00440;&#x00435;&#x00433;&#x00443;&#x0043b;&#x0044f;&#x00440;&#x0043d;&#x0044b;&#x00445; &#x0043f;&#x0043e;&#x00434;&#x00441;&#x00447;&#x00435;&#x00442;&#x0043e;&#x00432; &#x0043a;&#x0043e;&#x0043b;&#x00438;&#x00447;&#x00435;&#x00441;&#x00442;&#x00432;&#x00430; CD4+ T-&#x0043b;&#x00438;&#x0043c;&#x00444;&#x0043e;&#x00446;&#x00438;&#x00442;&#x0043e;&#x00432;.</p></sec></trans-abstract></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>The CD4+ T-lymphocyte count is the method recommended by the World Health Organization (WHO) to assess eligibility for antiretroviral treatment (ART).<xref rid="R1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="R2" ref-type="bibr"><sup>2</sup></xref> The CD4+ count also guides the clinical management of people living with human immunodeficiency virus (HIV).<xref rid="R2" ref-type="bibr"><sup>2</sup></xref> WHO recommends testing of viral load to detect treatment failure, but the CD4+ count continues to be used for ART monitoring if viral load cannot be tested.<xref rid="R3" ref-type="bibr"><sup>3</sup></xref> In settings where viral load can be determined, WHO suggests that routine CD4+ monitoring may be reduced or stopped for adults who are virologically stable.<xref rid="R4" ref-type="bibr"><sup>4</sup></xref><sup>,</sup><xref rid="R5" ref-type="bibr"><sup>5</sup></xref>
</p><p>Increased availability of ART has driven the establishment of laboratories analysing CD4+ count, but access to CD4+ testing requires adequate laboratory capacity and the means to transport specimens.<xref rid="R6" ref-type="bibr"><sup>6</sup></xref><sup>,</sup><xref rid="R7" ref-type="bibr"><sup>7</sup></xref> Point-of-care CD4+ testing provides rapid results without the need to transport specimens and is considered an important tool to improve patient retention in care before treatment initiation.<xref rid="R8" ref-type="bibr"><sup>8</sup></xref><sup>&#x02013;</sup><xref rid="R11" ref-type="bibr"><sup>11</sup></xref></p><p>The Alere Pima CD4+ analyser (Alere Technologies, Jena, Germany) was commercially launched in 2010. It is an automated analyser intended for counting CD4+ cells in capillary or venous whole blood within 20 minutes. The analyser is portable; can be operated with a rechargeable battery; contains dried thermostable reagents and can be stored at room temperature. The analyser performs a series of checks to ensure that all steps of the analysis are completed successfully, if not, an invalid result is reported. It is recommended that internal Pima Bead cartridges are analysed daily for quality control purposes. The analyser fulfils most WHO criteria for point-of-care tests<xref rid="R12" ref-type="bibr"><sup>12</sup></xref> and is on the WHO list of prequalified diagnostics.<xref rid="R13" ref-type="bibr"><sup>13</sup></xref></p><p>The analyser has been extensively evaluated with favourable diagnostic performance at laboratory level<xref rid="R14" ref-type="bibr"><sup>14</sup></xref><sup>&#x02013;</sup><xref rid="R25" ref-type="bibr"><sup>25</sup></xref> and with acceptable results at clinic level,<xref rid="R26" ref-type="bibr"><sup>26</sup></xref><sup>&#x02013;</sup><xref rid="R40" ref-type="bibr"><sup>40</sup></xref> in mobile clinics<xref rid="R41" ref-type="bibr"><sup>41</sup></xref> and in communities.<xref rid="R42" ref-type="bibr"><sup>42</sup></xref><sup>,</sup><xref rid="R43" ref-type="bibr"><sup>43</sup></xref> Some studies showed higher variability of results at clinic level with capillary sampling.<xref rid="R44" ref-type="bibr"><sup>44</sup></xref><sup>&#x02013;</sup><xref rid="R46" ref-type="bibr"><sup>46</sup></xref> A recent meta-analysis showed that the analyser was comparable in performance to laboratory-based methods. The analyser identifies patients for treatment at the 350&#x000a0;CD4+&#x000a0;cells/&#x003bc;L threshold with a sensitivity of 91.6% and specificity of 94.8%.<xref rid="R47" ref-type="bibr"><sup>47</sup></xref></p><p>In 2011, M&#x000e9;decins Sans Fronti&#x000e8;res (MSF) introduced the analyser in various projects to make CD4+ counting more accessible and to reduce loss to follow-up. During the implementation phase, several MSF sites reported a relatively high proportion of errors. Previous studies have reported invalid results ranging from 2% to 15%.<xref rid="R29" ref-type="bibr"><sup>29</sup></xref><sup>,</sup><xref rid="R32" ref-type="bibr"><sup>32</sup></xref><sup>,</sup><xref rid="R38" ref-type="bibr"><sup>38</sup></xref><sup>,</sup><xref rid="R39" ref-type="bibr"><sup>39</sup></xref> However, these studies have been conducted under validation conditions and there is a lack of data describing errors under routine field conditions. Given the relatively high proportion of invalid results reported at MSF sites, we carried out a retrospective analysis of analyser data across a variety of settings. The objective of the study was to describe the proportion of CD4+ test errors and identify factors associated with these errors. We hypothesized that invalid results might be related to the experience of the operators or to the type of blood sample used.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Study population</title><p>We conducted a retrospective, observational, cross-sectional study using routine data from 39 MSF-supported sites using the analyser in the Central African Republic, the Democratic Republic of the Congo, Guinea, India, Kenya, Lesotho, Malawi, Mozambique and South Africa, between 1 January 2011 and 30 June 2013. Analysers were introduced in laboratories, primary health-care clinics, mobile clinics and in communities. HIV-positive individuals requiring ART eligibility assessment, and in some instances, ART monitoring, had CD4+ counts done on capillary or venous blood samples. The study protocol was submitted to the MSF ethics review board and exempted from ethics review because it complied with the standards for routinely collected data analyses.</p></sec><sec><title>Training</title><p>Laboratory technicians, clinicians and lay workers, were trained either by MSF-trained personnel or by the local Alere representative before use of the analyser. On-site training was conducted in half a day and focused on device operation, sampling technique, quality control and data management. In Lesotho and South Africa, a three-day centralized course in Alere&#x02019;s training department in Cape Town was also provided to key staff who, in turn, trained multiple users on-site.</p></sec><sec><title>Sampling technique</title><p>Venous blood samples were used at all sites in the Central African Republic, the Democratic Republic of the Congo, Guinea, India, Kenya, Malawi and two sites in South Africa; capillary sampling was used in Lesotho, Mozambique and the remaining nine sites in South Africa. All sites in the Central African Republic, the Democratic Republic of the Congo, Guinea, India, Kenya and Malawi used a fixed volume micropipette to transfer 25&#x000a0;&#x000b5;L of venous blood to the cartridge. Two sites in South Africa used a plain capillary tube for cartridge filling. Capillary sampling was performed using the Alere recommended safety lancet (Sarstedt, N&#x000fc;mbrecht, Germany) at remaining sites in South Africa and all sites in Mozambique and Lesotho.</p></sec><sec><title>Quality control</title><p>Daily quality control was done at all sites using the manufacturer-supplied bead standards (with normal and low CD4+ cell counts) before testing patient samples. Eleven sites in South Africa were also enrolled in a regional proficiency testing programme and tested stabilized whole blood samples with normal or low CD4+ counts every two months.<xref rid="R48" ref-type="bibr"><sup>48</sup></xref> At most sites, dedicated paper-based registers were implemented to capture test results. None of the sites made use of the Alere online data portal during the study period. Test results and quality control data were analysed periodically in each country by a laboratory coordinator.</p></sec><sec><title>Data collection</title><p>Archived computer files containing CD4+ test results and quality control data were collated from each device. Information about the setting, user, training, sampling technique and device repair history were obtained by questionnaire, completed by the laboratory coordinator in each country. To ensure a representative number of tests per device and to eliminate errors due to inexperienced operators, we excluded data from devices with less than&#x02009;50 tests, users performing less than&#x02009;50 tests or unknown operators.</p></sec><sec><title>Analysis</title><p>We calculated the proportion of invalid CD4+ test results by device and by operator. Factors associated with invalid results were analysed using the binreg command in Stata version 13.0 (StataCorp. LP, College Station, United States of America). To determine the effects of user type and setting, we performed a series of analyses, restricted to those countries with comparable user type and setting.</p><p>We carried out the following comparisons: (i)&#x000a0;tests done at clinics by lay workers versus tests done by clinicians in South Africa; (ii)&#x000a0;tests done by laboratory technicians at clinics versus tests done at laboratories in the Central African Republic and the Democratic Republic of the Congo, and (iii)&#x000a0;tests done by lay health workers in mobile settings versus tests done in clinics in Lesotho, Mozambique and South Africa. For each of these three comparisons, we calculated the frequency of errors stratified by country and tested for effect modification by country using the Mantel-Haenszel <italic>&#x003c7;<sup>2</sup></italic> test. If there was no effect modification by country, we used generalized linear regression models to assess associations between error frequency and user type or setting. The <italic>&#x003c7;</italic><sup>2</sup> test for categorical variables and the two-sample test of proportions were used to assess the significance of differences; a <italic>P</italic>-value of less than&#x02009;0.05 was considered statistically significant.</p></sec></sec><sec sec-type="results"><title>Results</title><p>Between January 2011 and June 2013, there were 27&#x02009;019 records in the data set. The exclusion criteria led to 1403 tests being removed, leaving 25&#x02009;616 records from nine countries, across 39 sites, for 58 devices and 180 end-users. The characteristics of the participating sites are shown in <xref ref-type="table" rid="T1">Table&#x000a0;1</xref>. Most tests were done in fixed clinics (13&#x02009;892; 54.2%), followed by home-based testing (5913; 23.1%), mobile clinics (3924; 15.3%) and laboratories (1887; 7.4%). Tests were done by laboratory staff (8230; 32.0%), clinicians (8188; 32.0%) and lay workers (9198; 36.0%). Most tests were done on venous blood (15&#x02009;596; 61.0%) and the remainder on capillary blood (10&#x02009;020; 39.0%). The median number of users per device was 3 (interquartile range, IQR: 2&#x02013;5); the median number of tests per device was 470 (IQR: 252&#x02013;672) and the median number of tests per user was 106 (IQR: 50&#x02013;216).</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Characteristics of participating sites, nine countries, 2011&#x02013;2013</title></caption><table frame="hsides" rules="groups"><col width="90" span="1"/><col width="106" span="1"/><col width="117" span="1"/><col width="144" span="1"/><col width="56" span="1"/><col width="60" span="1"/><col width="48" span="1"/><col width="84" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Country</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Sample type</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">User type</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Settings</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Users, No.</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Devices, No.</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Tests, No.</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Invalid tests, No. (%)</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Central African Republic</td><td valign="top" align="left" rowspan="1" colspan="1">Venous blood</td><td valign="top" align="left" rowspan="1" colspan="1">Laboratory technician</td><td valign="top" align="left" rowspan="1" colspan="1">1 clinic, 1 laboratory</td><td valign="top" align="center" rowspan="1" colspan="1">10</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">1925</td><td valign="top" align="center" rowspan="1" colspan="1">362 (18.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Democratic Republic of the Congo</td><td valign="top" align="left" rowspan="1" colspan="1">Venous blood</td><td valign="top" align="left" rowspan="1" colspan="1">Laboratory technician, clinician</td><td valign="top" align="left" rowspan="1" colspan="1">2 laboratories, 2 clinics, 1&#x000a0;mobile clinic</td><td valign="top" align="center" rowspan="1" colspan="1">25</td><td valign="top" align="center" rowspan="1" colspan="1">5</td><td valign="top" align="center" rowspan="1" colspan="1">1888</td><td valign="top" align="center" rowspan="1" colspan="1">254 (13.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Guinea</td><td valign="top" align="left" rowspan="1" colspan="1">Venous blood</td><td valign="top" align="left" rowspan="1" colspan="1">Laboratory technician</td><td valign="top" align="left" rowspan="1" colspan="1">2 clinics</td><td valign="top" align="center" rowspan="1" colspan="1">10</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">1896</td><td valign="top" align="center" rowspan="1" colspan="1">150 (7.9)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">India</td><td valign="top" align="left" rowspan="1" colspan="1">Venous blood</td><td valign="top" align="left" rowspan="1" colspan="1">Laboratory technician</td><td valign="top" align="left" rowspan="1" colspan="1">2 clinics</td><td valign="top" align="center" rowspan="1" colspan="1">5</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">1235</td><td valign="top" align="center" rowspan="1" colspan="1">60 (4.9)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Kenya</td><td valign="top" align="left" rowspan="1" colspan="1">Venous blood</td><td valign="top" align="left" rowspan="1" colspan="1">Laboratory technician, clinician</td><td valign="top" align="left" rowspan="1" colspan="1">2 clinics, 2 laboratories, mobile clinics<sup>a</sup></td><td valign="top" align="center" rowspan="1" colspan="1">26</td><td valign="top" align="center" rowspan="1" colspan="1">11</td><td valign="top" align="center" rowspan="1" colspan="1">5717</td><td valign="top" align="center" rowspan="1" colspan="1">670 (11.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Lesotho</td><td valign="top" align="left" rowspan="1" colspan="1">Capillary blood</td><td valign="top" align="left" rowspan="1" colspan="1">Clinician, lay worker</td><td valign="top" align="left" rowspan="1" colspan="1">6 clinics, 3 mobile clinics</td><td valign="top" align="center" rowspan="1" colspan="1">40</td><td valign="top" align="center" rowspan="1" colspan="1">10</td><td valign="top" align="center" rowspan="1" colspan="1">4434</td><td valign="top" align="center" rowspan="1" colspan="1">681 (15.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Malawi</td><td valign="top" align="left" rowspan="1" colspan="1">Venous blood</td><td valign="top" align="left" rowspan="1" colspan="1">Clinician</td><td valign="top" align="left" rowspan="1" colspan="1">Mobile clinics<sup>a</sup></td><td valign="top" align="center" rowspan="1" colspan="1">10</td><td valign="top" align="center" rowspan="1" colspan="1">7</td><td valign="top" align="center" rowspan="1" colspan="1">1520</td><td valign="top" align="center" rowspan="1" colspan="1">358 (23.6)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Mozambique</td><td valign="top" align="left" rowspan="1" colspan="1">Capillary blood</td><td valign="top" align="left" rowspan="1" colspan="1">Lay worker</td><td valign="top" align="left" rowspan="1" colspan="1">Mobile clinics</td><td valign="top" align="center" rowspan="1" colspan="1">6</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">1554</td><td valign="top" align="center" rowspan="1" colspan="1">136 (8.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">South Africa</td><td valign="top" align="left" rowspan="1" colspan="1">Venous, capillary</td><td valign="top" align="left" rowspan="1" colspan="1">Clinician, lay worker</td><td valign="top" align="left" rowspan="1" colspan="1">8 clinics, 3 mobile clinics</td><td valign="top" align="center" rowspan="1" colspan="1">49</td><td valign="top" align="center" rowspan="1" colspan="1">16</td><td valign="top" align="center" rowspan="1" colspan="1">5447</td><td valign="top" align="center" rowspan="1" colspan="1">683 (12.5)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><bold>Total</bold></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"><bold>39</bold></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>180</bold></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>58</bold></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>25&#x02009;616</bold></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>3354 (13.1)</bold></td></tr></tbody></table><table-wrap-foot><p><sup>a</sup> Home-based testing.</p></table-wrap-foot></table-wrap><sec><title>Invalid results</title><p>There were 3354 invalid results: (13.1%) overall; with 4.9% for India, 7.9% for Guinea, 8.8% for Mozambique, 11.7% for Kenya, 13.4% for the Democratic Republic of the Congo, 12.5% for South Africa, 15.4% for Lesotho, 18.8% for the Central African Republic and 23.6% for Malawi. There were 12.7% errors per device (IQR: 10.3&#x02013;19.9) and 12.1% per user (IQR: 7.1&#x02013;19.2).</p></sec><sec><title>Source of errors</title><p>The most common errors were code 850 (37.0%) and code 880 (18.0%). These errors can result from multiple causes (<xref ref-type="fig" rid="F1">Fig.&#x000a0;1</xref>). Based on the error codes, the source of the error was the user (1542; 46.0%); user or device (1519; 45.3%); device (83; 2.5%); or sample (147; 4.4%); with the remaining 63 errors (1.9%) being of unknown origin (<xref ref-type="fig" rid="F2">Fig.&#x000a0;2</xref>). For calibration tests using Pima beads, 2% generated errors (207/10&#x02009;404), with error codes 203 and 840 being the most common.</p><fig id="F1" fig-type="figure" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Types of error using the Alere Pima CD4+ analyser for CD4+ T-lymphocyte counts, (<italic>n</italic>=3354), nine countries, 2011&#x02013;2013</p></caption><graphic xlink:href="BLT.14.146480-F1"/></fig><fig id="F2" fig-type="figure" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Sources of error using the Alere Pima CD4+ analyser for CD4+ T-lymphocyte counts, (<italic>n</italic>=3354), nine countries, 2011&#x02013;2013</p></caption><graphic xlink:href="BLT.14.146480-F2"/></fig></sec><sec><title>Associated factors</title><p>The factors associated with invalid tests are shown in <xref ref-type="table" rid="T2">Table&#x000a0;2</xref>. Compared to South Africa, invalid tests were lowest in India (risk ratio; RR: 0.36; 95% confidence interval, CI: 0.27&#x02013;0.46) and highest in Malawi (RR: 1.72; 95% CI: 1.50&#x02013;1.97). Compared to tests done in 2013, there were fewer invalid tests in 2011 and 2012, but there was no significant secular trend. Users were significantly more likely to experience invalid results within their first 50 tests, but once they had done 50 tests or more, there was no trend towards a lower frequency of invalid results as their level of experience increased further. The frequency of errors was not correlated with the number of users per device.</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Factors associated with errors using the Alere Pima CD4+ analyser for CD4+ T-lymphocyte counts, nine countries, 2011&#x02013;2013</title></caption><table frame="hsides" rules="groups"><col width="133" span="1"/><col width="120" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Characteristic</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">RR (95% CI)</th></tr></thead><tbody><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Country</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">South Africa</td><td valign="top" align="center" rowspan="1" colspan="1">(reference)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Central African Republic</td><td valign="top" align="center" rowspan="1" colspan="1">1.47 (12.9&#x02013;1.66)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Democratic Republic of the Congo</td><td valign="top" align="center" rowspan="1" colspan="1">1.04 (0.90&#x02013;1.20)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Guinea</td><td valign="top" align="center" rowspan="1" colspan="1">0.60 (0.50&#x02013;0.71)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">India</td><td valign="top" align="center" rowspan="1" colspan="1">0.36 (0.27&#x02013;0.46)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Kenya</td><td valign="top" align="center" rowspan="1" colspan="1">1.02 (0.92&#x02013;1.13)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Lesotho</td><td valign="top" align="center" rowspan="1" colspan="1">1.19 (1.07&#x02013;1.32)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Malawi</td><td valign="top" align="center" rowspan="1" colspan="1">1.72 (1.50&#x02013;1.97)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Mozambique</td><td valign="top" align="center" rowspan="1" colspan="1">0.65 (0.54&#x02013;0.78)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Time period</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">2013</td><td valign="top" align="center" rowspan="1" colspan="1">(reference)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">2011</td><td valign="top" align="center" rowspan="1" colspan="1">0.88 (0.77&#x02013;1.02)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">2012</td><td valign="top" align="center" rowspan="1" colspan="1">0.81 (0.74&#x02013;0.89)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Cumulative operator experience</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">1&#x02013;49 tests</td><td valign="top" align="center" rowspan="1" colspan="1">(reference)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">50&#x02013;99 tests</td><td valign="top" align="center" rowspan="1" colspan="1">0.86 (0.78&#x02013;0.94)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">100&#x02013;199 tests</td><td valign="top" align="center" rowspan="1" colspan="1">0.88 (0.81&#x02013;0.97)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02265;&#x02009;200 tests</td><td valign="top" align="center" rowspan="1" colspan="1">0.90 (0.83&#x02013;0.99)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Operators per device</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">1 operator</td><td valign="top" align="center" rowspan="1" colspan="1">(reference)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">2&#x02013;3 operators</td><td valign="top" align="center" rowspan="1" colspan="1">1.06 (0.97&#x02013;1.17)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">4&#x02013;5 operators</td><td valign="top" align="center" rowspan="1" colspan="1">1.09 (0.98&#x02013;1.20)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02265;&#x02009;6 operators</td><td valign="top" align="center" rowspan="1" colspan="1">0.93 (0.83&#x02013;1.03)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Sample Type</bold><sup>a</sup></td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Venous blood</td><td valign="top" align="center" rowspan="1" colspan="1">(reference)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Capillary blood</td><td valign="top" align="center" rowspan="1" colspan="1">0.46 (0.40&#x02013;0.53)</td></tr></tbody></table><table-wrap-foot><p>CI: confidence interval; RR: risk ratio.</p><p><sup>a</sup> Sub-analysis restricted to South Africa.</p></table-wrap-foot></table-wrap><p>In clinics in South Africa, errors were significantly less frequent for lay health workers than clinicians (9.9% versus 19.8%; <italic>P</italic>&#x02009;=&#x02009;0.001). Among laboratory technicians, the association between setting and the frequency of invalid tests differed by country. In the Central African Republic, invalid tests among laboratory technicians were more frequent at the clinic than at the laboratory (22.4% versus 16.3%; <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001), while in the Democratic Republic of the Congo, invalid tests among laboratory technicians were less frequent at the clinic than at the laboratory (13.2% versus 18.7%; <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001). Among lay health workers in Lesotho, Mozambique and South Africa, the association between setting and the frequency of invalid tests differed by country: in South Africa and Lesotho, the frequency of invalid tests was comparable in mobile clinic and fixed clinic settings (9.0% versus 9.9% in South Africa; <italic>P</italic>&#x02009;=&#x02009;0.35; and 15.5% versus 16.1% in Lesotho; <italic>P</italic>&#x02009;=&#x02009;0.66). However, in Mozambique, the frequency of invalid tests in mobile clinics was considerably lower than in fixed clinics (4.1% versus 13.6%; <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001).</p></sec><sec><title>Blood sample type</title><p>There were fewer invalid results when capillary blood samples were used (12.0%, versus 14.0% for venous blood samples; <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001). In a subgroup multivariate analysis restricted to South Africa, (the only country in which both sample types were used) this association was strengthened (RR: 0.46; 95% CI: 0.40&#x02013;0.53).</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>Under routine field conditions, the proportion of invalid CD4+ test results ranged from 5% in India to 24% in Malawi. Previous studies have reported comparable ratios from 5% in Thailand to 19% in South Africa.<xref rid="R15" ref-type="bibr"><sup>15</sup></xref><sup>,</sup><xref rid="R33" ref-type="bibr"><sup>33</sup></xref> In our study, invalid results were slightly more frequent in venous blood samples than capillary blood samples. The use of a pipette to fill the device cartridge may generate air bubbles; since the CD4+ test is based on image detection, the presence of air bubbles may affect the results. To decrease the generation of air bubbles, the manufacturer recommends that capillary tubes instead of pipettes be used to transfer venous blood to the device. Studies in Senegal and Uganda reported more errors using capillary blood specimens (14% and 18%) compared to venous blood specimens (5% and 8%).<xref rid="R31" ref-type="bibr"><sup>31</sup></xref><sup>,</sup><xref rid="R44" ref-type="bibr"><sup>44</sup></xref> However, other studies using venous blood have also found high ratios of invalid results: 10% in Ethiopia, 11% in USA and 15% in South Africa.<xref rid="R16" ref-type="bibr"><sup>16</sup></xref><sup>,</sup><xref rid="R18" ref-type="bibr"><sup>18</sup></xref><sup>,</sup><xref rid="R45" ref-type="bibr"><sup>45</sup></xref> Some studies have shown an increased variability of Alere Pima CD4+ results when capillary blood is used.<xref rid="R20" ref-type="bibr"><sup>20</sup></xref><sup>,</sup><xref rid="R44" ref-type="bibr"><sup>44</sup></xref><sup>,</sup><xref rid="R45" ref-type="bibr"><sup>45</sup></xref> However, a recent systematic review and meta-analysis found that capillary blood yielded more accurate results than venous blood.<xref rid="R47" ref-type="bibr"><sup>47</sup></xref> The fact that errors were more likely to occur using venous blood in our study may be related to the pipetting skills of laboratory staff. Therefore, training of laboratory staff in pipetting skills is as important as training clinic staff to perform capillary bleeds required for field testing.</p><p>The proportion of invalid samples for calibration tests was low (2%); however, in some instances, operators did not know how to interpret the results, so that testing continued despite clear indication of a problem; this calls for retraining. Multiple factors probably contribute to the wide variability of invalid results among countries, sites, devices and operators in our study. We did not find a clear association between the number of operators per device, the type of operator or the setting. Prospective studies under field conditions, specifically designed to evaluate the effect of various factors on the invalid tests are needed.</p><p>There were several limitations resulting from the retrospective nature of our study. We could not analyse errors according to cartridge lot number because this information was not contained in the cartridge barcode and sites did not document lot numbers systematically. It proved impossible to identify lot numbers via orders, as they were placed through various procurement centres in Europe as well as purchased from local distributors. We were unable to link results of repeat testing due to errors, so it was not possible to estimate the proportion of valid or invalid results after a second test. During the study period, none of the sites made use of online data systems for the analyser. Remote analysers can be connected to a centralised data warehouse via the internet, which could improve the timeliness of monitoring.</p><p>The high proportion of invalid CD4+ test results, necessitating the use of a second cartridge, raises the cost of testing per patient.<xref rid="R49" ref-type="bibr"><sup>49</sup></xref> Overall, 3354 tests had to be repeated; at a current price of 6&#x000a0;United States dollars (US$) per test, this translates to a cost of US$&#x000a0;20&#x02009;124. Repeat tests take time to process, decrease throughput, and oblige the patient to provide another blood sample if capillary sampling is used.</p><p>Training, monitoring, quality assessment and troubleshooting are essential aspects of point-of-care testing.<xref rid="R50" ref-type="bibr"><sup>50</sup></xref> It is important that post-market surveillance is done regularly and manufacturers continue to make the necessary improvements to their technologies and to supply service, maintenance and training for the full lifespan of the device.</p><p>In conclusion, 13.1% of results from the Alere Pima CD4+ analyser were invalid in this study. Most errors could be attributed to the operator but elucidating the exact cause proved to be difficult. Analyser errors are frequent and need to be factored into the implementation and operational cost for routine CD4+ testing.</p></sec></body><back><ack><title>Acknowledgements</title><p>We thank the MSF Laboratory Working Group, the staff in the nine projects, Ralph Labugger (Alere, Germany) and Greg Khoury (Alere, South Africa).</p></ack><fn-group><title>Funding:</title><fn fn-type="supported-by"><p>This study was funded by M&#x000e9;decins Sans Fronti&#x000e8;res, Operational Centre Brussels, Belgium.</p></fn></fn-group><fn-group><title>Competing interests:</title><fn fn-type="financial-disclosure"><p>None declared.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><mixed-citation publication-type="journal"><string-name><surname>Munthali</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Taegtmeyer</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Garner</surname>
<given-names>PG</given-names></string-name>, <string-name><surname>Lalloo</surname>
<given-names>DG</given-names></string-name>, <string-name><surname>Squire</surname>
<given-names>SB</given-names></string-name>, <string-name><surname>Corbett</surname>
<given-names>EL</given-names></string-name>, <etal>et al.</etal>
<article-title>Diagnostic accuracy of the WHO clinical staging system for defining eligibility for ART in sub-Saharan Africa: a systematic review and meta-analysis.</article-title>
<source>J Int AIDS Soc</source>. <year>2014</year>;<volume>17</volume>(<issue>1</issue>):<fpage>18932</fpage>. <pub-id pub-id-type="doi">10.7448/IAS.17.1.18932</pub-id><pub-id pub-id-type="pmid">24929097</pub-id></mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="web">Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach. Geneva: World Health Organization; 2013. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/hiv/pub/guidelines/arv2013/download/en/">http://www.who.int/hiv/pub/guidelines/arv2013/download/en/</ext-link> [cited 2015 May 27].</mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="web">Technical and operational considerations for implementing HIV viral load testing: interim technical update. Geneva: World Health Organization; 2014. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/hiv/pub/arv/viral-load-testing-technical-update/en/">http://www.who.int/hiv/pub/arv/viral-load-testing-technical-update/en/</ext-link><ext-link ext-link-type="uri" xlink:href="http://"/><ext-link ext-link-type="uri" xlink:href="http://www.who.int/hiv/pub/guidelines/arv2013/download/en/">http://www.who.int/hiv/pub/guidelines/arv2013/download/en/</ext-link> [cited 2015 May 27].</mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="book"><source>Supplement to the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach.</source>
<publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization</publisher-name>; <year>2014</year>.</mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="journal"><string-name><surname>Ford</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Meintjes</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Pozniak</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Bygrave</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Hill</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Peter</surname>
<given-names>T</given-names></string-name>, <etal>et al.</etal>
<article-title>The future role of CD4 cell count for monitoring antiretroviral therapy.</article-title>
<source>Lancet Infect Dis</source>. <year>2015</year>
<month>2</month>;<volume>15</volume>(<issue>2</issue>):<fpage>241</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(14)70896-5</pub-id><pub-id pub-id-type="pmid">25467647</pub-id></mixed-citation></ref><ref id="R6"><label>6</label><mixed-citation publication-type="book"><source>The availability and use of diagnostics for HIV: a 2012/2013 WHO survey of low- and middle-income countries.</source>
<publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization</publisher-name>; <year>2014</year>.</mixed-citation></ref><ref id="R7"><label>7</label><mixed-citation publication-type="journal"><string-name><surname>Peter</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Badrichani</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Wu</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Freeman</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Ncube</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Ariki</surname>
<given-names>F</given-names></string-name>, <etal>et al.</etal>
<article-title>Challenges in implementing CD4 testing in resource-limited settings.</article-title>
<source>Cytometry B Clin Cytom</source>. <year>2008</year>;<volume>74</volume>(<issue>S1</issue>) <supplement>Suppl 1</supplement>:<fpage>S123</fpage>&#x02013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1002/cyto.b.20416</pub-id><pub-id pub-id-type="pmid">18348208</pub-id></mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="journal"><string-name><surname>Mugglin</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Estill</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Wandeler</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Bender</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Egger</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Gsponer</surname>
<given-names>T</given-names></string-name>, <etal>et al.</etal>; <collab>IeDEA Southern Africa</collab>. <article-title>Loss to programme between HIV diagnosis and initiation of antiretroviral therapy in sub-Saharan Africa: systematic review and meta-analysis.</article-title>
<source>Trop Med Int Health</source>. <year>2012</year>
<month>12</month>;<volume>17</volume>(<issue>12</issue>):<fpage>1509</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-3156.2012.03089.x</pub-id><pub-id pub-id-type="pmid">22994151</pub-id></mixed-citation></ref><ref id="R9"><label>9</label><mixed-citation publication-type="journal"><string-name><surname>Kranzer</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Govindasamy</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Ford</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Johnston</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Lawn</surname>
<given-names>SD</given-names></string-name>. <article-title>Quantifying and addressing losses along the continuum of care for people living with HIV infection in sub-Saharan Africa: a systematic review.</article-title>
<source>J Int AIDS Soc</source>. <year>2012</year>;<volume>15</volume>(<issue>2</issue>):<fpage>17383</fpage>. <pub-id pub-id-type="doi">10.7448/IAS.15.2.17383</pub-id><pub-id pub-id-type="pmid">23199799</pub-id></mixed-citation></ref><ref id="R10"><label>10</label><mixed-citation publication-type="journal"><string-name><surname>Rosen</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Fox</surname>
<given-names>MP</given-names></string-name>. <article-title>Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review.</article-title>
<source>PLoS Med</source>. <year>2011</year>
<month>7</month>;<volume>8</volume>(<issue>7</issue>):<fpage>e1001056</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pmed.1001056</pub-id><pub-id pub-id-type="pmid">21811403</pub-id></mixed-citation></ref><ref id="R11"><label>11</label><mixed-citation publication-type="journal"><string-name><surname>Wynberg</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Cooke</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Shroufi</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Reid</surname>
<given-names>SD</given-names></string-name>, <string-name><surname>Ford</surname>
<given-names>N</given-names></string-name>. <article-title>Impact of point-of-care CD4 testing on linkage to HIV care: a systematic review.</article-title>
<source>J Int AIDS Soc</source>. <year>2014</year>;<volume>17</volume>(<issue>1</issue>):<fpage>18809</fpage>. <pub-id pub-id-type="doi">10.7448/IAS.17.1.18809</pub-id><pub-id pub-id-type="pmid">24447595</pub-id></mixed-citation></ref><ref id="R12"><label>12</label><mixed-citation publication-type="journal"><string-name><surname>Wu</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Zaman</surname>
<given-names>MH</given-names></string-name>. <article-title>Low-cost tools for diagnosing and monitoring HIV infection in low-resource settings.</article-title>
<source>Bull World Health Organ</source>. <year>2012</year>
<month>12</month>
<day>1</day>;<volume>90</volume>(<issue>12</issue>):<fpage>914</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.2471/BLT.12.102780</pub-id><pub-id pub-id-type="pmid">23284197</pub-id></mixed-citation></ref><ref id="R13"><label>13</label><mixed-citation publication-type="web">Public report for WHO Prequalification of diagnostic programme, public report. Product: Pima&#x02122; CD4+ Test. Number: PQDx 0099-032-00. Geneva: World Health Organization; 2011. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/diagnostics_laboratory/evaluations/111208_0099_032_00_public_report_v2.pdf">http://www.who.int/diagnostics_laboratory/evaluations/111208_0099_032_00_public_report_v2.pdf</ext-link><ext-link ext-link-type="uri" xlink:href="http://"/>[cited 2015 May 27].</mixed-citation></ref><ref id="R14"><label>14</label><mixed-citation publication-type="confproc">Mermond S, Blair DH, Magnat E, Tourancheau S, Lartigue M, Garvez AM, et al. Evaluation of a simple, low throughput and low cost CD4+ t-cell enumeration platform. In: Proceedings of the 22nd Annual Conference of the Australasian Society for HIV Medicine; 2010 Oct 20&#x02013;22; Sydney, Australia. Darlinghurst: Australasian Society for HIV Medicine; 2010.</mixed-citation></ref><ref id="R15"><label>15</label><mixed-citation publication-type="journal"><string-name><surname>Sukapirom</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Onlamoon</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Thepthai</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Polsrila</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Tassaneetrithep</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Pattanapanyasat</surname>
<given-names>K</given-names></string-name>. <article-title>Performance evaluation of the Alere PIMA CD4 test for monitoring HIV-infected individuals in resource-constrained settings.</article-title>
<source>J Acquir Immune Defic Syndr</source>. <year>2011</year>
<month>10</month>
<day>1</day>;<volume>58</volume>(<issue>2</issue>):<fpage>141</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1097/QAI.0b013e31822866a2</pub-id><pub-id pub-id-type="pmid">21709568</pub-id></mixed-citation></ref><ref id="R16"><label>16</label><mixed-citation publication-type="confproc">Tegbaru B, Messele T, Abebe A, Teshome D, Hailu E, Challa F, et al. Evaluation of a point of care-CD4+ testing in Ethiopia [Vol WELBD05. Oral Abstract Session]. Proceedings of the 6<sup>th</sup> IAS Conference on HIV Pathogenesis, Treatment and Prevention; 2011 July 17&#x02013;20; Rome, Italy.</mixed-citation></ref><ref id="R17"><label>17</label><mixed-citation publication-type="book">Baker CK, Mayes A, Smith J, Lusack A, Gascoigne-Barnett S. Evaluating the Point-of-Care Alere&#x02122; PIMA&#x000ae; CD4+ Test with the traditional laboratory Flow Cytometer. Northampton: Northampton General Hospital Pathology Department; 2012. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.alere.co.uk/pdf/031111025702-Evaluating%20the%20POC%20Pima%20CD4+%20test%20poster-%20Northampton%20%28lab%29.pdf">http://www.alere.co.uk/pdf/031111025702-Evaluating%20the%20POC%20Pima%20CD4+%20test%20poster-%20Northampton%20%28lab%29.pdf</ext-link><ext-link ext-link-type="uri" xlink:href="http://"/>[cited 2015 May 27]. </mixed-citation></ref><ref id="R18"><label>18</label><mixed-citation publication-type="web">Evaluation report: Pima CD4+ Assay. Atlanta: Centers for Disease Control and Prevention; 2012. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.biolinker.com.ar/productos/PDF_ALERE/Pima%20educ/Pima%20Evaluation%20Report%20CDC.pdf">http://www.biolinker.com.ar/productos/PDF_ALERE/Pima%20educ/Pima%20Evaluation%20Report%20CDC.pdf</ext-link> [cited 2015 May 27].</mixed-citation></ref><ref id="R19"><label>19</label><mixed-citation publication-type="journal"><string-name><surname>Yothipitak</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Wiwattanasorn</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Somboon</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Nothawian</surname>
<given-names>S</given-names></string-name>. <article-title>A comparative study of CD4++ T-lymphocyte counts between Alere PIMA CD4+ point-of-care and Standard Flow Cytometry methods.</article-title>
<source>J Med Tech Assoc Thailand.</source>
<year>2012</year>;<volume>40</volume>:<fpage>2</fpage>.</mixed-citation></ref><ref id="R20"><label>20</label><mixed-citation publication-type="journal"><string-name><surname>Mwau</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Adungo</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Kadima</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Njagi</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Kirwaye</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Abubakr</surname>
<given-names>NS</given-names></string-name>, <etal>et al.</etal>
<article-title>Evaluation of PIMA&#x02122;&#x000ae; point of care technology for CD4 T cell enumeration in Kenya.</article-title>
<source>PLoS ONE</source>. <year>2013</year>;<volume>8</volume>(<issue>6</issue>):<fpage>e67612</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0067612</pub-id><pub-id pub-id-type="pmid">23825674</pub-id></mixed-citation></ref><ref id="R21"><label>21</label><mixed-citation publication-type="journal"><string-name><surname>Rathunde</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Kussen</surname>
<given-names>GMB</given-names></string-name>, <string-name><surname>Beltrame</surname>
<given-names>MP</given-names></string-name>, <string-name><surname>Dalla Costa</surname>
<given-names>LM</given-names></string-name>, <string-name><surname>Raboni</surname>
<given-names>SM</given-names></string-name>. <article-title>Evaluation of the Alere Pima&#x02122; for CD4+ T lymphocytes counts in HIV-positive outpatients in Southern Brazil.</article-title>
<source>Int J STD AIDS</source>. <year>2014</year>
<month>11</month>;<volume>25</volume>(<issue>13</issue>):<fpage>956</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1177/0956462414526862</pub-id><pub-id pub-id-type="pmid">24616116</pub-id></mixed-citation></ref><ref id="R22"><label>22</label><mixed-citation publication-type="journal"><string-name><surname>Wade</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Daneau</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Aboud</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Vercauteren</surname>
<given-names>GH</given-names></string-name>, <string-name><surname>Urassa</surname>
<given-names>WS</given-names></string-name>, <string-name><surname>Kestens</surname>
<given-names>L</given-names></string-name>. <article-title>WHO multicenter evaluation of FACSCount CD4 and Pima CD4 T-cell count systems: instrument performance and misclassification of HIV-infected patients.</article-title>
<source>J Acquir Immune Defic Syndr</source>. <year>2014</year>
<month>8</month>
<day>15</day>;<volume>66</volume>(<issue>5</issue>):<fpage>e98</fpage>&#x02013;<lpage>107</lpage>. <pub-id pub-id-type="doi">10.1097/QAI.0000000000000214</pub-id><pub-id pub-id-type="pmid">24853304</pub-id></mixed-citation></ref><ref id="R23"><label>23</label><mixed-citation publication-type="web">Zeh C, Inzaule SC, Otieno F, Oyaro B, Ndivo R, Rose CE, et al. Evaluation of Pima CD4+ point-of-care device in western Kenya for potential use in field settings [Abstract 624]. In: Proceedings of the 21st Conference on Retroviruses and Opportunistic Infections; 2014 Mar 3&#x02013;6; Boston, USA. Atlanta: Centers for Disease Control and Prevention; 2014. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.croiconference.org/sites/all/abstracts/624.pdf">http://www.croiconference.org/sites/all/abstracts/624.pdf</ext-link> [cited 2015 May 27].</mixed-citation></ref><ref id="R24"><label>24</label><mixed-citation publication-type="web">Malia J, Manak M, Lombardi K, Crawford K, Giese R, Bryant M, et al. Clinical evaluation of PIMA point of care assay for evaluation of CD4+ cell counts [Poster THPDB0202]. In: Proceedings of 20th International AIDS Conference; 2014 Jul 20&#x02013;25; Melbourne, Australia. Geneva: International AIDS Society: 2014. Available from: <ext-link ext-link-type="uri" xlink:href="http://pag.aids2014.org/Abstracts.aspx?AID=2067">http://pag.aids2014.org/Abstracts.aspx?AID=2067</ext-link> [cited 2015 May 27].</mixed-citation></ref><ref id="R25"><label>25</label><mixed-citation publication-type="web">Collino Perez CJG, Gallego Gonzalez F. Evaluaci&#x000f3;n metodol&#x000f3;gica del equipamiento pima para la cuantificaci&#x000f3;n de linfocitos T CD4+. Argentina: Ministerio de Salud de la Provincia de C&#x000f3;rdoba; 2014. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.academia.edu/11400645/Evaluaci%C3%B3n_Metodol%C3%B3gica_del_equipamiento_PIMA_para_la_cuantificaci%C3%B3n_de_Linfocitos_T_CD4+">https://www.academia.edu/11400645/Evaluaci%C3%B3n_Metodol%C3%B3gica_del_equipamiento_PIMA_para_la_cuantificaci%C3%B3n_de_Linfocitos_T_CD4+</ext-link> [cited 2015 May 27]. Spanish.</mixed-citation></ref><ref id="R26"><label>26</label><mixed-citation publication-type="journal"><string-name><surname>Mtapuri-Zinyowera</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Chideme</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Mangwanya</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Mugurungi</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Gudukeya</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Hatzold</surname>
<given-names>K</given-names></string-name>, <etal>et al.</etal>
<article-title>Evaluation of the PIMA point-of-care CD4 analyzer in VCT clinics in Zimbabwe.</article-title>
<source>J Acquir Immune Defic Syndr</source>. <year>2010</year>
<month>9</month>;<volume>55</volume>(<issue>1</issue>):<fpage>1</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1097/QAI.0b013e3181e93071</pub-id><pub-id pub-id-type="pmid">20622679</pub-id></mixed-citation></ref><ref id="R27"><label>27</label><mixed-citation publication-type="journal"><string-name><surname>Jani</surname>
<given-names>IV</given-names></string-name>, <string-name><surname>Sitoe</surname>
<given-names>NE</given-names></string-name>, <string-name><surname>Chongo</surname>
<given-names>PL</given-names></string-name>, <string-name><surname>Alfai</surname>
<given-names>ER</given-names></string-name>, <string-name><surname>Quevedo</surname>
<given-names>JI</given-names></string-name>, <string-name><surname>Tobaiwa</surname>
<given-names>O</given-names></string-name>, <etal>et al.</etal>
<article-title>Accurate CD4 T-cell enumeration and antiretroviral drug toxicity monitoring in primary healthcare clinics using point-of-care testing.</article-title>
<source>AIDS</source>. <year>2011</year>
<month>3</month>
<day>27</day>;<volume>25</volume>(<issue>6</issue>):<fpage>807</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1097/QAD.0b013e328344f424</pub-id><pub-id pub-id-type="pmid">21378535</pub-id></mixed-citation></ref><ref id="R28"><label>28</label><mixed-citation publication-type="journal"><string-name><surname>Mnyani</surname>
<given-names>CN</given-names></string-name>, <string-name><surname>McIntyre</surname>
<given-names>JA</given-names></string-name>, <string-name><surname>Myer</surname>
<given-names>L</given-names></string-name>. <article-title>The reliability of point-of-care CD4 testing in identifying HIV-infected pregnant women eligible for antiretroviral therapy.</article-title>
<source>J Acquir Immune Defic Syndr</source>. <year>2012</year>
<month>7</month>
<day>1</day>;<volume>60</volume>(<issue>3</issue>):<fpage>260</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1097/QAI.0b013e318256b651</pub-id><pub-id pub-id-type="pmid">22487589</pub-id></mixed-citation></ref><ref id="R29"><label>29</label><mixed-citation publication-type="journal"><string-name><surname>Thakar</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Mahajan</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Shaikh</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Bagwan</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Sane</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Kabra</surname>
<given-names>S</given-names></string-name>, <etal>et al.</etal>
<article-title>Utility of the point of care CD4 analyzer, PIMA, to enumerate CD4 counts in the field settings in India.</article-title>
<source>AIDS Res Ther</source>. <year>2012</year>;<volume>9</volume>(<issue>1</issue>):<fpage>26</fpage>. <pub-id pub-id-type="doi">10.1186/1742-6405-9-26</pub-id><pub-id pub-id-type="pmid">22998738</pub-id></mixed-citation></ref><ref id="R30"><label>30</label><mixed-citation publication-type="journal"><string-name><surname>Herbert</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Edwards</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Carrick</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Copas</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Sandford</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Amphlett</surname>
<given-names>M</given-names></string-name>, <etal>et al.</etal>
<article-title>Evaluation of PIMA point-of-care CD4 testing in a large UK HIV service.</article-title>
<source>Sex Transm Infect</source>. <year>2012</year>
<month>10</month>;<volume>88</volume>(<issue>6</issue>):<fpage>413</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1136/sextrans-2012-050507</pub-id><pub-id pub-id-type="pmid">22544309</pub-id></mixed-citation></ref><ref id="R31"><label>31</label><mixed-citation publication-type="journal"><string-name><surname>Manabe</surname>
<given-names>YC</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Elbireer</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Auerbach</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Castelnuovo</surname>
<given-names>B</given-names></string-name>. <article-title>Evaluation of portable point-of-care CD4 counter with high sensitivity for detecting patients eligible for antiretroviral therapy.</article-title>
<source>PLoS ONE</source>. <year>2012</year>;<volume>7</volume>(<issue>4</issue>):<fpage>e34319</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0034319</pub-id><pub-id pub-id-type="pmid">22536323</pub-id></mixed-citation></ref><ref id="R32"><label>32</label><mixed-citation publication-type="journal"><string-name><surname>Myer</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Daskilewicz</surname>
<given-names>K</given-names></string-name>, <string-name><surname>McIntyre</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Bekker</surname>
<given-names>LG</given-names></string-name>. <article-title>Comparison of point-of-care versus laboratory-based CD4 cell enumeration in HIV-positive pregnant women.</article-title>
<source>J Int AIDS Soc</source>. <year>2013</year>;<volume>16</volume>(<issue>1</issue>):<fpage>18649</fpage>. <pub-id pub-id-type="doi">10.7448/IAS.16.1.18649</pub-id><pub-id pub-id-type="pmid">24044627</pub-id></mixed-citation></ref><ref id="R33"><label>33</label><mixed-citation publication-type="journal"><string-name><surname>Gous</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Scott</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Potgieter</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Ntabeni</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Enslin</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Newman</surname>
<given-names>R</given-names></string-name>, <etal>et al.</etal>
<article-title>Feasibility of performing multiple point of care testing for HIV anti-retroviral treatment initiation and monitoring from multiple or single fingersticks.</article-title>
<source>PLoS ONE</source>. <year>2013</year>;<volume>8</volume>(<issue>12</issue>):<fpage>e85265</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0085265</pub-id><pub-id pub-id-type="pmid">24376873</pub-id></mixed-citation></ref><ref id="R34"><label>34</label><mixed-citation publication-type="journal"><string-name><surname>Wade</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Diaw</surname>
<given-names>PA</given-names></string-name>, <string-name><surname>Daneau</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Camara</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Dieye</surname>
<given-names>TN</given-names></string-name>, <string-name><surname>Mboup</surname>
<given-names>S</given-names></string-name>, <etal>et al.</etal>
<article-title>CD4 T-cell enumeration in a field setting: evaluation of CyFlow counter using the CD4 easy count kit-dry and Pima CD4 systems.</article-title>
<source>PLoS ONE</source>. <year>2013</year>;<volume>8</volume>(<issue>9</issue>):<fpage>e75484</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0075484</pub-id><pub-id pub-id-type="pmid">24066184</pub-id></mixed-citation></ref><ref id="R35"><label>35</label><mixed-citation publication-type="journal"><string-name><surname>Morawski</surname>
<given-names>BM</given-names></string-name>, <string-name><surname>Meya</surname>
<given-names>DB</given-names></string-name>, <string-name><surname>Boulware</surname>
<given-names>DR</given-names></string-name>. <article-title>Accuracy of pima point-of-care CD4 analyzer in routine use in public health clinics in Uganda.</article-title>
<source>J Acquir Immune Defic Syndr</source>. <year>2013</year>
<month>7</month>
<day>1</day>;<volume>63</volume>(<issue>3</issue>):<fpage>e113</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1097/QAI.0b013e3182928f27</pub-id><pub-id pub-id-type="pmid">23760094</pub-id></mixed-citation></ref><ref id="R36"><label>36</label><mixed-citation publication-type="web">Su YZ, Jia MH, Jiang Y, Xiao Y, Shi YH, Chen HC, et al. [Evaluation of PIMA analyzer detecting CD4+ cell count of venous and capillary blood in HIV-infected individuals]. Zhonghua Yu Fang Yi Xue Za Zhi. 2013 Nov;47(11):1001&#x02013;5. Chinese.</mixed-citation></ref><ref id="R37"><label>37</label><mixed-citation publication-type="journal"><string-name><surname>Galiwango</surname>
<given-names>RM</given-names></string-name>, <string-name><surname>Lubyayi</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Musoke</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Kalibbala</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Buwembo</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Kasule</surname>
<given-names>J</given-names></string-name>, <etal>et al.</etal>
<article-title>Field evaluation of PIMA point-of-care CD4 testing in Rakai, Uganda.</article-title>
<source>PLoS ONE</source>. <year>2014</year>;<volume>9</volume>(<issue>3</issue>):<fpage>e88928</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0088928</pub-id><pub-id pub-id-type="pmid">24614083</pub-id></mixed-citation></ref><ref id="R38"><label>38</label><mixed-citation publication-type="journal"><string-name><surname>Malagun</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Nano</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Chevallier</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Opina</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Sawiya</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Kivavia</surname>
<given-names>J</given-names></string-name>, <etal>et al.</etal>
<article-title>Multisite evaluation of point of care CD4 testing in Papua New Guinea.</article-title>
<source>PLoS ONE</source>. <year>2014</year>;<volume>9</volume>(<issue>11</issue>):<fpage>e112173</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0112173</pub-id><pub-id pub-id-type="pmid">25426710</pub-id></mixed-citation></ref><ref id="R39"><label>39</label><mixed-citation publication-type="journal"><string-name><surname>Picken</surname>
<given-names>SC</given-names></string-name>, <string-name><surname>Williams</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Harvey</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Esser</surname>
<given-names>MM</given-names></string-name>. <article-title>The routine paediatric human immunodeficiency virus visit as an intervention opportunity for failed maternal care and use of point-of-care CD4+ testing as an adjunct in determining antiretroviral therapy eligibility.</article-title>
<source>South Afr J Infect Dis</source>. <year>2014</year>;<volume>29</volume>(<issue>2</issue>):<fpage>70</fpage>&#x02013;<lpage>4</lpage>.</mixed-citation></ref><ref id="R40"><label>40</label><mixed-citation publication-type="confproc">Mupfumi L, Mine M, Moyo M, Matsuokwane T, Mogashoa T, Mugisha K, et al. Evaluation of CD4+ enumeration by non-laboratory personnel using PIMA point of care (POC) instruments in rural clinics in Tutume Sub-District in northern Botswana [Abstract 1.23]. In: Second International Conference African Society of Laboratory Medicine; 2014. Nov 30&#x02013;Dec 4; Cape Town, South Africa.</mixed-citation></ref><ref id="R41"><label>41</label><mixed-citation publication-type="confproc">Van Scha&#x000ef;k N, Kranzer K, Myer L, Raditlhalo E, et al. Field validation of the PIMA&#x02122; Analyzer in a mobile clinic setting in South Africa [Poster No. V-144]. In: Proceedings of the 18th Conference on Retroviruses and Opportunistic Infections; 2011 Feb 27&#x02013;Mar 2; Boston, USA. San Francisco: CROI Foundation; 2011. </mixed-citation></ref><ref id="R42"><label>42</label><mixed-citation publication-type="journal"><string-name><surname>van Rooyen</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Barnabas</surname>
<given-names>RV</given-names></string-name>, <string-name><surname>Baeten</surname>
<given-names>JM</given-names></string-name>, <string-name><surname>Phakathi</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Joseph</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Krows</surname>
<given-names>M</given-names></string-name>, <etal>et al.</etal>
<article-title>High HIV testing uptake and linkage to care in a novel program of home-based HIV counseling and testing with facilitated referral in KwaZulu-Natal, South Africa.</article-title>
<source>J Acquir Immune Defic Syndr</source>. <year>2013</year>
<month>9</month>
<day>1</day>;<volume>64</volume>(<issue>1</issue>):<fpage>e1</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1097/QAI.0b013e31829b567d</pub-id><pub-id pub-id-type="pmid">23714740</pub-id></mixed-citation></ref><ref id="R43"><label>43</label><mixed-citation publication-type="web">Moyo S, Okui L, Bussmann H, Gaseitsiwe S, van Widenfeldt E, Holme MP, et al. Accuracy of POC CD4+ testing using microtube capillary sampling in Botswana households [Abstract 630]. In: Proceedings of the Annual Conference on Retroviruses and Opportunistic Infections; 2015 Feb 23&#x02013;26; Seattle, USA. San Francisco: CROI Foundation; 2015. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.croiconference.org/sites/default/files/posters-2015/630.pdf">http://www.croiconference.org/sites/default/files/posters-2015/630.pdf</ext-link> [cited 2015 May 27]. </mixed-citation></ref><ref id="R44"><label>44</label><mixed-citation publication-type="journal"><string-name><surname>Diaw</surname>
<given-names>PA</given-names></string-name>, <string-name><surname>Daneau</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Coly</surname>
<given-names>AA</given-names></string-name>, <string-name><surname>Ndiaye</surname>
<given-names>BP</given-names></string-name>, <string-name><surname>Wade</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Camara</surname>
<given-names>M</given-names></string-name>, <etal>et al.</etal>
<article-title>Multisite evaluation of a point-of-care instrument for CD4(+) T-cell enumeration using venous and finger-prick blood: the PIMA CD4.</article-title>
<source>J Acquir Immune Defic Syndr</source>. <year>2011</year>
<month>12</month>
<day>1</day>;<volume>58</volume>(<issue>4</issue>):<fpage>e103</fpage>&#x02013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1097/QAI.0b013e318235b378</pub-id><pub-id pub-id-type="pmid">21909029</pub-id></mixed-citation></ref><ref id="R45"><label>45</label><mixed-citation publication-type="journal"><string-name><surname>Glencross</surname>
<given-names>DK</given-names></string-name>, <string-name><surname>Coetzee</surname>
<given-names>LM</given-names></string-name>, <string-name><surname>Faal</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Masango</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Stevens</surname>
<given-names>WS</given-names></string-name>, <string-name><surname>Venter</surname>
<given-names>WF</given-names></string-name>, <etal>et al.</etal>
<article-title>Performance evaluation of the Pima&#x02122; point-of-care CD4 analyser using capillary blood sampling in field tests in South Africa.</article-title>
<source>J Int AIDS Soc</source>. <year>2012</year>;<volume>15</volume>(<issue>1</issue>):<fpage>3</fpage>. <pub-id pub-id-type="doi">10.1186/1758-2652-15-3</pub-id><pub-id pub-id-type="pmid">22284546</pub-id></mixed-citation></ref><ref id="R46"><label>46</label><mixed-citation publication-type="journal"><string-name><surname>Pinto</surname>
<given-names>IC</given-names></string-name>, <string-name><surname>Sabid&#x000f3;</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Pereira</surname>
<given-names>AB</given-names></string-name>, <string-name><surname>Mello</surname>
<given-names>MB</given-names></string-name>, <string-name><surname>de Melo Xavier Shimizu</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Protti</surname>
<given-names>BL</given-names></string-name>, <etal>et al.</etal>
<article-title>Field Evaluation of a Point-of-Care CD4 Analyzer for Monitoring HIV Patients in the Interior of the Amazon Region, Brazil.</article-title>
<source>PLoS ONE</source>. <year>2015</year>;<volume>10</volume>(<issue>4</issue>):<fpage>e0121400</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0121400</pub-id><pub-id pub-id-type="pmid">25905775</pub-id></mixed-citation></ref><ref id="R47"><label>47</label><mixed-citation publication-type="journal"><string-name><surname>Wilkinson</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Chiavegatti</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Nauche</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Joseph</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Pai</surname>
<given-names>NP</given-names></string-name>. <article-title>Head to head comparisons in performance of CD4+ point-of-care assays: a Bayesian meta-analysis (2000-2013).</article-title>
<source>Sci Open Res</source>. <year>2014</year>
<month>7</month>;<volume>11</volume>:<fpage>1</fpage>&#x02013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.14293/S2199-1006.1.SOR-MED.A4QF5Y.v1</pub-id></mixed-citation></ref><ref id="R48"><label>48</label><mixed-citation publication-type="journal"><string-name><surname>Glencross</surname>
<given-names>DK</given-names></string-name>, <string-name><surname>Aggett</surname>
<given-names>HM</given-names></string-name>, <string-name><surname>Stevens</surname>
<given-names>WS</given-names></string-name>, <string-name><surname>Mandy</surname>
<given-names>F</given-names></string-name>. <article-title>African regional external quality assessment for CD4 T-cell enumeration: development, outcomes, and performance of laboratories.</article-title>
<source>Cytometry B Clin Cytom</source>. <year>2008</year>;<volume>74</volume>(<issue>S1</issue>) <supplement>Suppl 1</supplement>:<fpage>S69</fpage>&#x02013;<lpage>79</lpage>. <pub-id pub-id-type="doi">10.1002/cyto.b.20397</pub-id><pub-id pub-id-type="pmid">18228560</pub-id></mixed-citation></ref><ref id="R49"><label>49</label><mixed-citation publication-type="journal"><string-name><surname>Larson</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Schnippel</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Ndibongo</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Long</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Fox</surname>
<given-names>MP</given-names></string-name>, <string-name><surname>Rosen</surname>
<given-names>S</given-names></string-name>. <article-title>How to estimate the cost of point-of-care CD4 testing in program settings: an example using the Alere Pima Analyzer in South Africa.</article-title>
<source>PLoS ONE</source>. <year>2012</year>;<volume>7</volume>(<issue>4</issue>):<fpage>e35444</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0035444</pub-id><pub-id pub-id-type="pmid">22532854</pub-id></mixed-citation></ref><ref id="R50"><label>50</label><mixed-citation publication-type="journal"><string-name><surname>Stevens</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Gous</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Ford</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Scott</surname>
<given-names>LE</given-names></string-name>. <article-title>Feasibility of HIV point-of-care tests for resource-limited settings: challenges and solutions.</article-title>
<source>BMC Med</source>. <year>2014</year>;<volume>12</volume>(<issue>1</issue>):<fpage>173</fpage>. <pub-id pub-id-type="doi">10.1186/s12916-014-0173-7</pub-id><pub-id pub-id-type="pmid">25197773</pub-id></mixed-citation></ref></ref-list></back></article>